预约演示
更新于：2026-06-17
RSVpreF
呼吸道合胞病毒疫苗（辉瑞大药厂）
更新于：2026-06-17
概要
基本信息
药物类型 预防性疫苗 |
别名 recombinant respiratory syncytial virus pre-fusion F protein, water for injections(Pfizer)、Respiratory Syncytial Virus Vaccine、PF 06928316 + [4] |
作用方式 调节剂 |
作用机制 Respiratory syncytial virus F protein调节剂(呼吸道合胞病毒F蛋白调节剂) |
非在研适应症- |
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 加拿大 (2023-01-04), |
最高研发阶段(中国)暂停 |
特殊审评突破性疗法 (美国)、快速通道 (美国)、优先审评 (美国) |
登录后查看时间轴
关联
36
项与 呼吸道合胞病毒疫苗（辉瑞大药厂） 相关的临床试验NCT07235397
Evaluating the Benefits Of RSV MaternaL vAccination Using a Scottish National Dataset.
This study will use a retrospective cohort design and will be conducted within routinely collected national healthcare and statutory demographic datasets held by PHS and National Records of Scotland (NRS). As such, there will be no active enrollment of study participants, no direct contact with study participants, no collection of any primary data outside of the standard of care (SOC), and no requirement for informed consent.
This study design was chosen due to several advantages, over other possible designs, including the ability to evaluate incidence of study outcomes in exposed and unexposed infants, ability to follow infants longitudinally to evaluate study outcomes through 12 months of age, and ability to evaluate all-cause outcomes.
Study endpoints, including RSV-associated LRTD hospitalization and RSV-associated hospitalization, among infants born to ABRYSVO-vaccinated mothers (exposed group) will be compared with those among infants born to ABRYSVO-unvaccinated mothers (comparison group) initially from birth through 6 months of age, with later analysis from birth through 12 months as the infants reach this age threshold and their data become available.
This study design was chosen due to several advantages, over other possible designs, including the ability to evaluate incidence of study outcomes in exposed and unexposed infants, ability to follow infants longitudinally to evaluate study outcomes through 12 months of age, and ability to evaluate all-cause outcomes.
Study endpoints, including RSV-associated LRTD hospitalization and RSV-associated hospitalization, among infants born to ABRYSVO-vaccinated mothers (exposed group) will be compared with those among infants born to ABRYSVO-unvaccinated mothers (comparison group) initially from birth through 6 months of age, with later analysis from birth through 12 months as the infants reach this age threshold and their data become available.
开始日期2026-05-15 |
申办/合作机构 |
NCT07543380
A PHASE 3, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS CONSIDERED AT HIGH RISK OF SEVERE RSV DISEASE IN JAPAN
The purpose of the study is to learn about the immune response after a RSVpreF vaccination. This study is being conducted in Japan. RSV is a common virus that can cause infections of the lungs and airways.
The study is seeking participants who are:
* 18 to 59 years of age
* adults with health condition(s) that can put them at an increased risk of severe RSV disease
It will also learn about the safety of RSVpreF vaccination. The study lasts about 2 months. Adults need to visit the research site at least 2 times. The participant will receive a phone call 2 months after vaccination for health checks.
The study is seeking participants who are:
* 18 to 59 years of age
* adults with health condition(s) that can put them at an increased risk of severe RSV disease
It will also learn about the safety of RSVpreF vaccination. The study lasts about 2 months. Adults need to visit the research site at least 2 times. The participant will receive a phone call 2 months after vaccination for health checks.
开始日期2026-05-11 |
申办/合作机构 |
NCT07232706
Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination: a Randomised Controlled Trial in France as Part of the Pregnancy and Infant PrEparedness pLatform IN Europe - PIPELINE
RSV (which stands for Respiratory Syncytial Virus) is an infection that causes cold-like symptoms and is most common during winter months. Most people with RSV infection get better by themselves but babies and younger children can become very poorly. About 1 in 15 infants with confirmed RSV within the first 12 months of life will be hospitalised, and a very small proportion will be seriously ill and may die.
Currently there are two different prevention options that can be used to prevent RSV infection in babies. One is a vaccine given to the mother during pregnancy, and the other is a monoclonal antibody given by injection to the baby. Although both prevention options work well on their own and are safe, neither provides 100% protection to the infant. It is not known whether giving both medicines, one to the mother in pregnancy and one to the infant, would provide better protection than giving only one medicine - this is what the PIPELINE-RSV study will look at.
PIPELINE-RSV-France will recruit about 1000 pregnant women in France. A parallel trial, running across Europe (PIPELINE-RSV-International) will recruit about 1500 pregnant women in UK, Switzerland, the Netherlands and Belgium. The protocols will align on key aspects and the data will be analysed together. The study will include two study groups with different prevention options used in each: (1) an injection given to the baby at the beginning of RSV season, or (2) both a vaccine given to the mother in pregnancy and an injection given to the baby at around 4 months of age. Each mother-baby pair will be randomly allocated to group by a computer. The numbers of babies in each of these groups who acquire RSV will be compared. In some countries participating to the International trial, an other study groups may be available : (3) a vaccine given to the mother in pregnancy.
Pregnant women and their babies will be followed until the baby reaches 12 months of age. Information will be collected about medically-important side effects either the mother or the baby had from their medicine(s) and any symptoms of RSV the baby had. Visits with the mother and baby will occur at birth and 12 months later. The mother will complete questionnaires via a Web-based platform to report any non-routine in-person visits, once in pregnancy and after the baby is born twice a month or monthly (more often in the winter), to also report baby's symptoms, to report their trial experience when the baby is 4 and 12 months' old, and to provide their views on vaccination at birth, and when the baby is 4 and 12 months' old. If the baby develops symptoms that might be RSV, their mother or another caregiver will be asked to take a sample using a swab from the baby's nose or mouth, and to send it by post for testing to find out if the baby has RSV.
As well as the main research study, there are also some substudies. A questionnaire will be given to women who consent to take part, to find out their motivations for joining the study and how they prefer to receive information about taking part in studies. A small number of women will be asked to take part in a study to look at how mothers' and babies' immune systems respond to the two different study prevention options , and to investigate different ways of collecting samples from their babies. In addition, researchers will use data from the study to see whether giving both medicines is cost-effective compared with giving just one medicine.
Currently there are two different prevention options that can be used to prevent RSV infection in babies. One is a vaccine given to the mother during pregnancy, and the other is a monoclonal antibody given by injection to the baby. Although both prevention options work well on their own and are safe, neither provides 100% protection to the infant. It is not known whether giving both medicines, one to the mother in pregnancy and one to the infant, would provide better protection than giving only one medicine - this is what the PIPELINE-RSV study will look at.
PIPELINE-RSV-France will recruit about 1000 pregnant women in France. A parallel trial, running across Europe (PIPELINE-RSV-International) will recruit about 1500 pregnant women in UK, Switzerland, the Netherlands and Belgium. The protocols will align on key aspects and the data will be analysed together. The study will include two study groups with different prevention options used in each: (1) an injection given to the baby at the beginning of RSV season, or (2) both a vaccine given to the mother in pregnancy and an injection given to the baby at around 4 months of age. Each mother-baby pair will be randomly allocated to group by a computer. The numbers of babies in each of these groups who acquire RSV will be compared. In some countries participating to the International trial, an other study groups may be available : (3) a vaccine given to the mother in pregnancy.
Pregnant women and their babies will be followed until the baby reaches 12 months of age. Information will be collected about medically-important side effects either the mother or the baby had from their medicine(s) and any symptoms of RSV the baby had. Visits with the mother and baby will occur at birth and 12 months later. The mother will complete questionnaires via a Web-based platform to report any non-routine in-person visits, once in pregnancy and after the baby is born twice a month or monthly (more often in the winter), to also report baby's symptoms, to report their trial experience when the baby is 4 and 12 months' old, and to provide their views on vaccination at birth, and when the baby is 4 and 12 months' old. If the baby develops symptoms that might be RSV, their mother or another caregiver will be asked to take a sample using a swab from the baby's nose or mouth, and to send it by post for testing to find out if the baby has RSV.
As well as the main research study, there are also some substudies. A questionnaire will be given to women who consent to take part, to find out their motivations for joining the study and how they prefer to receive information about taking part in studies. A small number of women will be asked to take part in a study to look at how mothers' and babies' immune systems respond to the two different study prevention options , and to investigate different ways of collecting samples from their babies. In addition, researchers will use data from the study to see whether giving both medicines is cost-effective compared with giving just one medicine.
开始日期2026-05-06 |
100 项与 呼吸道合胞病毒疫苗（辉瑞大药厂） 相关的临床结果
登录后查看更多信息
100 项与 呼吸道合胞病毒疫苗（辉瑞大药厂） 相关的转化医学
登录后查看更多信息
100 项与 呼吸道合胞病毒疫苗（辉瑞大药厂） 相关的专利（医药）
登录后查看更多信息
494
项与 呼吸道合胞病毒疫苗（辉瑞大药厂） 相关的文献（医药）2026-12-31·Human Vaccines & Immunotherapeutics
Parental acceptability of new RSV preventive therapies for infants: A cross-sectional survey in Canada
Article
作者: Moss, Stephana Julia ; Lee, Janet S W ; Vadlamudi, Nirma Khatri ; Castillo, Eliana ; MacDonald, Shannon E ; Dubé, Ève ; Bolotin, Shelly ; Halperin, Scott A ; Fitzpatrick, Tiffany ; Manca, Terra ; Greyson, Devon ; MacDonald, Jade ; Buchan, Sarah A ; Comeau, Jeannette L ; Papenburg, Jesse ; Parsons Leigh, Jeanna ; Blanchard, Wade ; Halperin, Donna ; Brousseau, Nicholas ; Langley, Joanne M ; Brundin-Mather, Rebecca
Two new RSV immunization products exist for infants: a prenatal vaccine (RSVpreF) and a long-acting monoclonal antibody for infants (nirsevimab). While both showed promise in clinical trials, implementation has varied across jurisdictions. Before rollout in Canada, we conducted an anonymized, online survey with a nationally representative sample of 1,015 expectant and recent birth parents. The primary outcome was product acceptability (disagree, undecided, agree). Odds ratios (ORs) and 95% confidence intervals (CIs) identified factors associated with agreement or indecision versus disagreement. Approximately 49% (n = 499) were expecting; 51% (n = 516) had a baby in the past year. Overall, 72% (n = 727) agreed to receive a product: 61% (n = 624) for RSVpreF and 60% (n = 608) for nirsevimab. RSVpreF agreement was higher among older parents (e.g., OR = 3.64; 95% CI, 1.99-6.67 for age 25-34 versus 18-24 years), those with a university degree (OR = 3.65; 95% CI, 2.01-6.64 versus high school), higher income (OR = 2.31; 95% CI, 1.01-5.28 for ≥$150k versus <$40k), or receipt/intention for Tdap (OR = 3.76; 95% CI, 2.37-5.96 versus no receipt/intention) or influenza (OR = 2.04; 95% CI, 1.29-3.21) vaccines. Agreement was higher among parents of children without a high-risk medical condition compared to those with (OR = 2.32; 95% CI, 1.44-3.72). Similar trends were observed for nirsevimab, with lower agreement also noted among those who self-researched antibodies (OR = 0.51; 95% CI, 0.30-0.88 versus not). As most respondents rated product safety (76%), effectiveness (71%), and disease severity risk (70%) as important in decision-making, providing clear information on these, alongside communications targeted to subgroups with lower agreement, may optimize uptake as programs rollout.
2026-12-31·Human Vaccines & Immunotherapeutics
Mucosal immunization with an adenoviral vector expressing a prefusogenic F protein protects the upper and lower respiratory tracts of cotton rats against live respiratory syncytial virus challenge
Article
作者: Wang, Qiyao ; Wang, Shen ; Bao, Jianwei ; Lu, Shuangshuang ; Wu, Ke ; Xu, Long ; Mu, Ting ; Zhang, Ying ; Xie, Liang ; Ma, Tao ; Klein, Michel ; Sun, Bing
Respiratory syncytial virus (RSV) is a major cause of severe respiratory disease in infants, young children, and the elderly. Current licensed prefusogenic F-based RSV vaccines induce systemic immune responses through intramuscular injection. However, mucosal immunization will be required to elicit local sterilizing immunity to prevent virus replication in the nasopharynx and the lungs as well as virus shedding and transmission. Adenovirus vectors are a promising platform to develop RSV vaccines, but further evaluation of mucosal adenovirus-based prefusion F (preF) vaccines is still needed. In this study, we constructed a recombinant chimpanzee adenovirus serotype 68 vector expressing a second-generation disulfide-stabilized (DS2)trimeric preF protein (ChAd68-PreF). In mice, intranasal immunization with ChAd68-PreF induced dose-dependent increase in RSV-specific secretory IgA (sIgA) in the lower respiratory tract, demonstrating its capacity to elict mucosal immunity. Subsequently, in cotton rats, intratracheal instillation of ChAd68-PreF induced high cross-neutralizing antibody titers against RSV A and RSV B. After RSV A2 challenge, ChAd68-PreF vaccinated animals showed no detectable viral replication in the nose nor in the lungs. Moreover, ChAd68-PreF vaccination did not lead to enhanced respiratory disease (ERD) in cotton rats. These results demonstrate that mucosal delivery of ChAd68-PreF confers potent protective immunity against RSV with good safety profile, warranting further clinical development as a mucosa-targeting RSV vaccine for vulnerable populations.
2026-08-01·INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
RSV vaccination in immunocompromised adults
Article
作者: Fourati, Slim ; Launay, Odile ; Loubet, Paul
BACKGROUND:
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in immunocompromised adults, including solid organ and hematopoietic stem cell transplant recipients. Following the 2023 licensure of three RSV vaccines for older adults, increasing numbers of immunocompromised individuals have become eligible for vaccination, although these populations were largely excluded from pivotal phase 3 trials.
METHODS:
We synthesize emerging data from prospective immunogenicity studies and large real-world effectiveness analyses evaluating RSV vaccines in immunocompromised adults.
RESULTS:
Humoral immune responses are attenuated and heterogeneous, with seroconversion rates commonly ranging from 30-60% in transplant populations and strongly influenced by time since transplantation, lymphocyte counts, and exposure to antimetabolites such as mycophenolate. Despite reduced antibody responses, first-season vaccine effectiveness against hospitalization is generally between 65% and 75% in immunocompromised adults. Two-season analyses demonstrate waning protection, more pronounced than in immunocompetent individuals. Cellular immune responses, particularly CD4 T-cell responses, may be preserved despite diminished serologic responses, suggesting that antibody measurements alone may underestimate clinical protection.
CONCLUSION:
Although immunogenicity is reduced and durability shorter than in immunocompetent adults, RSV vaccination provides meaningful protection against severe disease. Optimization of vaccination timing, booster strategies, and integration of passive immunization approaches warrant further study in high-risk subgroups.
868
项与 呼吸道合胞病毒疫苗（辉瑞大药厂） 相关的新闻（医药）22 小时之前
·搜狐新闻
又一家疫苗企业向科创板发起冲击。作为一家成立已10年的医药企业，迈科康长期依赖创投输血维持运营，过去三年累计亏损已达11亿元。如今，随着核心产品陆续迈入临床后期，研发投入和运营费用将进一步攀升。此时冲刺科创板“补血”，已是势在必行。
5月27日，成都迈科康生物科技股份有限公司（以下简称“迈科康”）的科创板IPO申请正式获得受理，此次计划募资29.29亿元，对应估值超百亿元。
与其百亿估值形成反差的是，其近三年营收合计仅6000万元，累计亏损达11亿元。而亏损的核心主要是公司目前仍未有重磅产品上市，且研发投入每年还在大幅增长。
在此情形下，迈科康冲刺科创板，除为自身"补血"融资外，也意在为多年陪跑的创投机构打通IPO退出渠道。
3年亏11亿
5月27日，迈科康IPO获受理，此次IPO拟募资29.29亿元，对应估值超百亿元。
资料显示，迈科康是一家致力于创新疫苗和新型佐剂研发、生产和商业化的生物医药企业，搭建了一系列创新疫苗品种管线，覆盖传染性疾病及肿瘤防治领域。
据了解，全球已获批的6款新型佐剂技术长期被GSK、辉瑞等国际药企垄断。公司核心产品MKK100带状疱疹疫苗有望成为中国首个采用新型佐剂获批上市的国产疫苗，公司呼吸道合胞病毒RSV疫苗MKK900已进入III期临床试验阶段，有望成为首个获批上市的国产RSV疫苗。公司3款新型佐剂产品被纳入CEPI全球疫苗佐剂库，为国内被纳入品种最多的公司。
不过，从公司透露的几款疫苗预期的上市时点来看，迈科康带状孢疹疫苗以及RSV疫苗营收放量还需假以时日。
由于公司目前仍未有重磅产品上市，因此公司的营收仅在千万元阶段。招股书披露，2023年-2025年，迈科康通过子公司依思康医药对外销售兽用（含宠物）疫苗的原材料收入分别为1362万元、2,7397万元、2,7235万元，是当前公司经营性现金流的全部来源。
此外，2023-2025年，公司归母净利润分别亏损2.56亿、3.42亿、5亿元，累计亏损达11亿元。
究其原因，作为早期生物医药企业，研发投入是迈科康开支的主要成分。报告期，公司研发投入分别为2.16亿元、2.92亿元和4.04亿元，近三年研发投入超9亿，研发费用占营收比例高达1809%。
值得注意的是，虽然迈科康目前仍未有重磅产品上市，并且处于持续亏损中，但资本市场仍给予其超百亿估值，或源于市场基于迈科康带状疱疹疫苗、RSV疫苗在内的核心产品获批后营收放量的预期。
据了解，2024年，中国带状疱疹行业的市场规模约为37.9亿元，预计至2035年，中国带状疱疹疫苗行业的市场规模将达到约125.6亿元，2024年至2035年期间复合年增长率约为11.5%。
RSV方面，我国当前尚无已获批的RSV疫苗产品。根据灼识咨询预测，2026年，我国中老年RSV疫苗市场规模为2.12亿元，预计到2035年，市场规模将达到135.58亿元人民币。
高瓴“半路”套现
高比例研发开支与大幅亏损的背后，依靠的是迈科康9轮融资，外部投资者近20亿元投资款的持续“输血”。
截至本次IPO申报前，第一大股东谦鼎管理由实际控制人陈德祥全资控股，持股21.28%，持股平台科雅翔成持股7.27%，与谦鼎管理为一致行动人，实控人通过谦鼎管理及其一致行动人合计控制公司34.2637%表决权。
外部机构方面，招股书显示，深创投当前持股11.22%，国寿成达持股6.16%，瑞普医药持股3.52%，VSPR VIII持股3.74%，高瓴蓁恒持股2.14%，富达创投持股1.86%。
值得注意的是，高瓴早在2021年便入股迈科康，不过其在半路选择了套现部分股权。具体来看，高瓴旗下三只持股迈科康的基金分别为VSPR VIII、高瓴蓁恒和VNTR IX，三只基金构成一致行动关系，2023年，三者合计持股比例为9.9853%。
2025年10月，高瓴资本旗下高瓴蓁恒以及赵杰夫、崔桂勇等5名早期股东，通过将部分股权转让的方式合计套现1.12亿元。截至招股书披露日，当前高瓴系持有迈科康的股份比例已降至了6.283%。
而迈科康之所以能得到如此多顶级机构的青睐，或与创始人陈德祥在医药领域的丰富经验有关。
资料显示，陈德祥1991年获得免疫学、微生物学博士学位，1993年伯明翰大学博士后毕业结束，1993年至2016年期间，先后任诺华Novartis、辉瑞Pfizer、帕斯适宜卫生科技组织PATH疫苗研发部领导岗，拥有30年疫苗行业经验。
2016年，陈德祥回国设立了成都迈科康，希望打破海外垄断，实现国产新型佐剂和创新疫苗的自主研发与产业化，解决“卡脖子”问题。
另一位公司技术骨干胡业勤，毕业于武汉大学，获发育生物学博士学位，2009年至2020年期间，任武汉生物制品研究所有限责任公司菌研室主任兼菌苗室副主任，2020年至今，任迈科康生物首席技术官。
不过，此次IPO招股书一经披露，公司管理层治理的结构问题成为了舆论关注焦点。
具体来看，实控人配偶董丽春任公司副总经理，实控人妻弟董宜春任公司首席运营官，首席技术官胡业勤配偶担任公司市场部副总监，董事会秘书符浩配偶也担任公司市场部经理一职。系列家族抱团式架构，引发了外界对公司治理独立性和内控有效性的质疑。
竞对虎视眈眈
据了解，迈科康生物核心产品重组带状疱疹疫苗MKK100预计将于2027年获批上市。
不过，迈科康生物在招股书中指出，国内已获批两款带状疱疹疫苗，分别为百克生物的减毒活疫苗感维以及葛兰素史克GSK的重组蛋白疫苗欣安立适Shingrix。
除公司产品外，本土竞品绿竹生物、怡道生物以及瑞科生物的重组带状疱疹疫苗亦处于NDA评审阶段，公司产品上市后，可能会面临更为激烈的竞争环境。
另外，公司另一款核心产品呼吸道合胞病毒RSV疫苗，当前已进入III期临床试验阶段。全球RSV疫苗市场竞争处在白热化，辉瑞、Moderna都在追赶。
2026年2月，葛兰素史克GSK全球首款老年人RSV 疫苗Arexvy已在中国提交上市申请，辉瑞的Abrysvo在中国的临床试验申请也已获受理。
国内临床阶段的企业则包括艾棣维欣、三叶草生物等。轮状病毒疫苗市场，已上市产品包括默沙东的五价轮状疫苗和国内一款单价产品。
除了行业竞争白热化之外，公司招股书中还重点提及了原料扰动。
招股书显示，公司核心产品MKK100及MKK900所必需的部分佐剂原材料如QS-21系提取自天然皂苷的有机物质，其人工合成工艺复杂，技术要求高，目前主要依赖于植物萃取，全球范围内具备规模化生产能力且质量稳定的合格供应商数量有限。
尽管公司已与相关供应商建立良好的合作关系并签订长期供应协议，约定了优先供应及价格条款，但仍无法完全排除因生产中断、原材料源头（特定植物）供应波动产能受限、质量控制问题、全球产能紧张或国际贸易环境变化等因素导致关键佐剂原材料供应短缺、延迟或价格大幅波动的风险。
种种未知摆在眼前，融资上市或许是当前迈科康生物做大影响力，持续高比例研发开支、与竞争对手肉搏的最有力要素。返回搜狐，查看更多
2026-06-12
由百林科医药科技（上海）股份有限公司、上海临港产业大学生物医药学院抗体药物专业分院、蒲公英教育共同举办的“新型疫苗工艺开发案例分享及商业化变更策略”线上课程，已于2026年6月11日顺利完成，在本次直播中来自百林科医药科技（上海）股份有限公司的百林科苏州应用中心应用总监姜明总就以下几方面进行了精彩的分享：
新型疫苗行业背景
新型疫苗工艺开发案例
商业化变更策略
百林科解决方案
Q&A
课程回顾
关键词：新型疫苗、疫苗工艺开发、商业化变更、百林科解决方案
一、课程背景与目标
课程聚焦于新型疫苗领域的工艺开发效率与商业化变更管理能力，这两大能力在行业快速发展背景下，已成为影响产品上市速度和市场竞争力的关键因素。随着国内外疫苗产业的结构优化与出海需求日益迫切，企业面临从研发到生产全链条的合规性与效率双重挑战，亟需系统性的工艺开发思路和变更管理策略作为支撑。
本课程的核心目标是通过前沿案例启发与系统性变更思路的分享，帮助企业实现高效、合规、可落地的疫苗生产工艺体系建设。
具体而言，课程旨在帮助学员获得两方面的收获：
一是通过真实案例理解新型疫苗工艺开发的关键技术要点与路径选择；
二是建立从研发到商业化的变更管理系统性思路，提升应对合规与效率矛盾的实际操作能力。
二、核心内容回顾
01
疫苗发展
第一代（奠定基础，风险与挑战并存）
灭活疫苗：通过物理或化学方法将病原体杀灭制成
优点：安全性极高，稳定，易于储存运输。
缺点：常需多次加强接种。
减毒活疫苗：使用经过处理的活病原体，减弱毒性但仍保留复制能力。
优点：免疫力持久，多数只需接种1-2次。
缺点：免疫缺陷者、孕妇禁用，存在极低的毒力返毒风险
第二代（精准打击，安全性提升）
亚单位疫苗/重组蛋白疫苗：仅保留病原体的关键免疫原成分（如蛋白或多糖），去除有害部分。
优点：安全性最好，副作用少。
缺点：制备工艺复杂，常需佐剂增强免疫
第三代（引领未来，全面激发免疫系统）
第三代/前沿疫苗：主要指核酸疫苗（mRNA疫苗与DNA疫苗）和重组病毒载体疫苗（如腺病毒载体疫苗）。此类疫苗在新冠疫情中得到大规模验证，研发与更新速度快，可同时诱导体液免疫和细胞免疫。
病毒载体疫苗（Viral Vector Vaccine）：病毒载体疫苗只会复制出大量的抗原，能激发强大的免疫应答。病毒载体本身不会致病和自我复制，所以理论上很安全；而且同一种病毒载体，可以用来运送不同的遗传物质，这就能大大加速疫苗研发的过程。
02
新型疫苗工艺开发案例分享
带状疱疹疫苗路线选择及国内客户布局
截至 2026，国内带状疱疹疫苗竞争已从“2款已上市”进入“减毒活 + 重组蛋白(主导） + mRNA”多路线并行阶段;从国内布局看：绿竹生物与迈科康生物领跑重组蛋白路线，智飞生物、艾博生物等多家企业竞逐mRNA前沿。
CHO表达重组VZV案例1：
培养过程中，细胞密度最高到（Day8）11X10E6 ，活率维持在96.9%以上，蛋白表达量约为1.5g/L。
重组带疱疫苗项目7L规模完整上下游工艺均打通，待放大至50L规模。
重组VZV案例2：
两步层析后纯度已达到98%。
RSV疫苗路线选择及国内客户布局
所有已上市及在研领先管线几乎均以F蛋白（融合蛋白）的融合前构象（pre-F） 为核心抗原靶点。这背后的科学逻辑在于：Pre-F构象可诱导产生高效价的中和抗体，而一旦F蛋白与宿主细胞膜融合并折叠为Post-F构象后，其有效抗原表位大幅减少。RSV疫苗技术的每一次迭代，本质上是围绕“如何稳定、高效呈现Pre-F抗原”这一命题展开的平台创新。
路线一：重组蛋白亚单位疫苗（第二代疫苗）——当前主流
原理：通过CHO细胞等表达系统重组表达RSV Pre-F蛋白，联合佐剂系统制成疫苗。代表产品：GSK Arexvy（AS01E佐剂）、辉瑞 Abrysvo（无佐剂，RSV A和B双价）。
路线二：mRNA疫苗（第三代前沿疫苗）——保护效力最高
原理：将编码RSV Pre-F蛋白的mRNA序列包裹于脂质纳米颗粒（LNP）中，递送至人体细胞，利用细胞自身机制合成抗原蛋白，激发体液免疫和细胞免疫。
国内企业技术布局及竞争态势
目前，国内尚无自主研发的RSV疫苗获批上市，这一空白既是挑战也是机遇。GSK的Arexvy已在华提交上市申请并获受理，有望成为国内首款上市的RSV疫苗，但同时本土企业也正以多技术路线全速追赶。国内已有20多家企业获得RSV疫苗临床批件。
进度领先者：迈科康重组蛋白RSV疫苗是国内唯一进入III期临床的RSV疫苗，有望成为首个上市。
CHO表达RSV流程：
重组表达RSV案例分享：
百林科三步填料纯化法MaXtar® MMC初步层析捕获+MaXtar® Q+MaXtar® Butyl HR，纯度可达到99.5%。
03
商业化变更策略
工艺变更价值
工艺变更不是“找麻烦”，而是疫苗生产企业持续优化工艺、维持质量先进性、保证产品竞争力的重要手段。
随着疫苗监管法规的不断完善，企业必须通过工艺变更来满足新的合规要求。
疫苗从研发走向商业化，产能扩张是必经之路。
质量提升与工艺先进性：从“凭经验”到“标准化”。
变更不是倒退，而是通过更先进的技术手段提升产品质量的一致性和可控性。
降本增效与成本控制：从高成本到经济可及
如何应对变更
原则一：质量体系先行——稳健的药品质量体（PQS）是变更管理的根基，是持有人实施变更管理的组织保障和技术基础。
原则二：基于风险分类——科学+风险，风险等级决定管控强度：疫苗应用于健康人群且涉及重大公共卫生问题，因此变更类别的划分尤其审慎。建议持有人在变更前主动与CDE或省局沟通，提前明确变更类别和研究要求，这是降低申报风险最有效的方式之一。
原则三：质量可比核心——变更前后产品质量属性高度相似
变更未对产品的安全性、有效性产生不利影响。
可比性研究的设计强调多层次、递进式的证明逻辑：
第一层：药学可比性
第二层·非临床可比性（药学数据无法充分证明可比性时）
第三层：临床可比性（较低层次研究无法证实安全有效性影响时）
原则四：全生命周期管理——从研发到上市的持续管控
药品上市后变更管理属于药品全生命周期管理的一部分。持有人是疫苗上市后变更管理的责任主体，承担疫苗全生命周期管理义务，确保疫苗上市后符合不断更新的技术要求。
案例分享：流感病毒疫苗（上市后变更）
按流感生产批工艺，使用百林科Chromstar® 4FF层析柱进行小试试验，验证可行性。分别完成四价流感病毒4个不同亚型3批纯化工作。
实验结论：其HA回收率及卵清蛋白残留量与原工艺填料层析结果相差不大，符合质量要求，达到了纯化的效果。从图谱上可以看出，同一种样品的三次实验图谱基本完全重合，与目前商业化规模图谱具有可比性。
04
百林科解决方案
疫苗研发/生产流程 – 全流程覆盖
BioLink BR 在新型重组蛋白&VLP 疫苗等应用
在CHO-K1和CHO-DG44细胞上均有较优表现
CytoLinX® MO-50L质粒疫苗&mRNA疫苗应用
反应器生长数据趋势
50L MO 工艺参数
大肠杆菌培养趋势图
收获:第一次产量 425 ug/mL，第二次产量 583ug/mL。
一次性反应器优势：
百林科反应器自动控制响应快，DO、pH、温度控制稳定且精准，可减少人为操作误差，最大程度保障工艺的稳定性。
尾气后端袋子整个培养过程都是干燥的。
说明尾气冷凝效果非常好，单个滤器即可满足需求，可降低耗材使用成本。
HAP 在多糖疫苗中的应用
客户，肺炎多糖项目。小试、中试、商业批
（以上图片来源：姜明老师PPT）
关于苏州应用中心
专业平台： 拥有从细胞房、微生物实验室到纯化实验室、分析实验室及中试车间的完整功能平台。
尖端设备： 配备层析设备、关键分析设备以及其他辅助设备，包括百林科自主品牌及进口高端层析系统，确保工艺的可放大性与可靠性。
资深团队： 拥有一支平均经验超过5年的精英团队，成员兼具顶尖药企与跨国供应商的丰富实战背景，深刻理解工艺与产业需求。
全面服务： 提供从工艺开发、样品制备、验证服务到分析检测、装柱服务的全方位支持。
苏州应用中心主要服务介绍
上游工艺
细菌 / 细胞培养工艺开发
培养工艺确认与转移
小试与中试规模发酵备样
下游工艺
纯化工艺开发
纯化工艺确认与转移
小试与中试规模纯化备样
验证与培训
工艺表征、填料寿命验证
工艺培训课程
实操培训
苏州应用中心仪器概况
细胞培养
分离纯化
流体管理
分析检测
关于课程回放
关注我们的公众号“蒲公英教育”。
在公众号对话框中回复关键词“疫苗工艺开发”。
根据指引填写相关信息，信息填写完毕后，您将收到一条包含回放链接的消息。
点击关注“蒲公英教育”公众号
关于讲师课件
请添加工作人员微信：张老师，13162399526
关于「百林科医药科技（上海）股份有限公司」
百林科BioLink是一家为生命科学领域提供工艺解决方案的高新科技集团化企业，专注于重组蛋白药物、疫苗、抗体药物、细胞治疗、基因治疗及其它生物制品生产工程中的关键工艺设备与耗材的研发和制造，产品涵盖生物工艺领域的上游细胞培养、一次性配储液和下游层析、三滤、水化产品等工艺单元和工艺开发服务。
百林科建有生物制药一次性装备及耗材生产基地和研发平台、层析填料生产基地和研发中心、验证中心、应用中心及培训中心，员工人数近600人。凭借着雄厚的研发和生产实力，百林科已自主研发并生产一次性配储液系统、一次性生物反应器、三滤系统、层析系统、层析填料、原液分装及制剂罐装相关耗材、水化产品以及软件控制系统等生物工艺相关产品。
百林科的产品现已进入国内外多家知名生物制药企业，被广泛应用于抗体、疫苗、重组蛋白药物等研发和生产。目前，公司正在不断扩大和完善销售网络和服务体系，国内已在10多个省份设立子/分公司，并在德国、新加坡、印度设立了海外分支机构。
百林科将持续为生物制品行业提供高品质、安全、易验证、高性价比且供应链有保障的中国“智”造生物工艺整体解决方案。以“科技成就生命创想”为愿景，赋能生物技术，通达无限可能！
✦
•
✦
关于「上海临港产业大学」
上海临港产业大学（以下简称“产业大学”）是在上海市教委、市人社局的指导下，临港新片区管委会的支持下，临港五校的共同倡议下，于2020年12月18日，由临港集团和上海建桥学院共同发起成立的培养“高素质、高技能”人才的公共服务平台。产业大学现已成立包括智能制造、能工巧匠、智能物流、光电子、集成电路一院、集成电路二院、生物医药、医疗装备、人工智能、航空、低空经济、医工、大数据、绿色安全、网络信息安全、国际教育、现代服务、产业链数字化、教育元宇宙、高级法商融合在内的20家二级学院。五年来，产业大学已具备可培训项目达152项，其中85项能颁发包括技能、职称、学历（由合作院校颁发）、上岗在内的四类证书。
2021年3月，上海临港产业大学、上海临港奉贤经济发展有限公司、上海生物医药行业协会及蒲公英教育共同成立上海临港产业大学生物医药学院。2024年，生物医药学院实训基地(1000㎡)于临港新片区生命蓝湾投建完毕并投入运营，实现生物医药行业从新药研发、工艺开发、生产制造、质量管理、质量检测、工程设备等技术岗位的专业实训，以临港新片区为中心，为上海乃至全国生物医药产业提供技术及管理人才培训服务。
✦
•
✦
关于「蒲公英教育」
疫苗信使RNA
2026-06-10
Journal of Antimicrobial Chemotherapy Volume 81, Issue 1抗菌化疗杂志81卷 1期
https://academic.oup.com/jac/issue
50th Anniversary Collection（50周年纪念合集）
Review（综述）
1
Artificial intelligence for improving decision-making in bacterial infection management: a narrative review
人工智能在改善细菌感染治疗决策中的应用：一项叙述性综述
Anisia Talianu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf470, https://doi.org/10.1093/jac/dkaf470
Reviews（综述）
2
Evolving landscape of methicillin-resistant Staphylococcus pseudintermedius: the emergence of new epidemic waves across Europe, Asia and North America
耐甲氧西林中间型葡萄球菌的演变格局：欧洲、亚洲和北美洲新流行浪潮的出现
Lillian Rose Giarratana and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf340, https://doi.org/10.1093/jac/dkaf340
3
Azithromycin resistance in non-typhoidal Salmonella: a review
非伤寒沙门氏菌对阿奇霉素的耐药性：综述
Zhe Zhu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf341, https://doi.org/10.1093/jac/dkaf341
4
Antibiotic pharmacodynamics: from MIC to advanced metrics and their applications
抗生素药效动力学：从最低抑菌浓度到高级指标及其应用
Malin Andersson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf374, https://doi.org/10.1093/jac/dkaf374
5
Progress in the study of drug resistance mechanism of Bacillus cereus
蜡样芽孢杆菌耐药机制研究进展
Yuhang Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf399, https://doi.org/10.1093/jac/dkaf399
6
The curious constraints on clofazimine
氯法齐明的奇特限制
Maple Goh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf430, https://doi.org/10.1093/jac/dkaf430
7
Antiplasmid systems: a novel strategy to combat antibiotic resistance
抗质粒系统：对抗抗生素耐药性的新策略
Mohd Asim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf472, https://doi.org/10.1093/jac/dkaf472
Systematic Review（系统综述）
8
Coccidioidomycosis in Europe: a systematic literature review of epidemiology, treatment and outcomes
欧洲球孢子菌病：流行病学、治疗和预后的系统文献综述
Priya Shastri and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf407, https://doi.org/10.1093/jac/dkaf407
9
Systematic review of antimicrobial pharmacokinetic/pharmacodynamic indices in murine thigh and hollow fibre dose fractionation studies analysed with a standard method
用标准方法分析小鼠大腿和空心纤维剂量分次研究中的抗菌药物药代动力学/药效动力学指数的系统综述
Najla Alabdulkarim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf446, https://doi.org/10.1093/jac/dkaf446
Virtual Roundtable（虚拟圆桌会议）
10
Procalcitonin in the management of lower respiratory tract infection and sepsis
降钙素原在下呼吸道感染和败血症治疗中的应用
Ramy H Elshaboury and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf298, https://doi.org/10.1093/jac/dkaf298
Original Research（论著）
11
Model-based assessment of letermovir pharmacokinetics in allogeneic haematopoietic stem cell transplant recipients
来特莫韦在异基因造血干细胞移植受者中药代动力学的基于模型的评估
Chrisoula Tahtsidou and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf427, https://doi.org/10.1093/jac/dkaf427
12
In vitro exebacase (CF-301) activity against methicillin-susceptible or methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci strains isolated from patients with infective endocarditis
体外试验评估依拉环素（CF-301）对甲氧西林敏感或甲氧西林耐药金黄色葡萄球菌及凝固酶阴性葡萄球菌（从感染性心内膜炎患者中分离）的活性
María-Alexandra Cañas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf435, https://doi.org/10.1093/jac/dkaf435
13
Evaluation of subcutaneous amoxicillin/clavulanic acid pharmacokinetics as an alternative to the intravenous route in older patients—the PhASAge Study
评估皮下注射阿莫西林/克拉维酸药代动力学作为老年患者静脉给药替代方案——PhASAge研究
Nicolas Grégoire and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf381, https://doi.org/10.1093/jac/dkaf381
14
Real-life use of isavuconazole in Spanish children and adolescents
西班牙儿童和青少年中艾沙康唑的实际使用情况
Natalia Mendoza-Palomar and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf394, https://doi.org/10.1093/jac/dkaf394
15
No pharmacovigilance signal of intracranial hypertension associated with glycylcyclines: a FAERS-based disproportionality analysis
基于FAERS数据库的不成比例性分析：未发现甘氨酰环素类与颅内高压相关的药物警戒信号
Slobodan M Jankovic and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf395, https://doi.org/10.1093/jac/dkaf395
16
Posaconazole enteral tube administration in adults: pharmacokinetic target attainment of oral suspension compared with crushed delayed-release tablet
成人经肠内营养管给予泊沙康唑：口服混悬液与碾碎的缓释片的药代动力学目标达成情况比较
Nirjan Bhattarai and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf396, https://doi.org/10.1093/jac/dkaf396
17
Characterizing CYP3A4-mediated drug interactions: a fixed-sequence pharmacokinetic Chinese study of posaconazole and ruxolitinib in haematological malignancies
CYP3A4介导的药物相互作用特征：一项关于泊沙康唑和鲁索替尼在血液系统恶性肿瘤中的固定序列药代动力学中国研究
Beibei Liang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf398, https://doi.org/10.1093/jac/dkaf398
18
Differences in prescription for impetigo and cellulitis across years in three European countries
三个欧洲国家不同年份脓疱病和蜂窝织炎的处方差异
Thomas Bettuzzi and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf400, https://doi.org/10.1093/jac/dkaf400
19
β-Lactam concentrations monitored in the early phase of community-acquired sepsis in the intensive care unit
重症监护室社区获得性脓毒症早期阶段监测的β-内酰胺浓度
Karolina Liljedahl Prytz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf401, https://doi.org/10.1093/jac/dkaf401
20
Enhanced antimycobacterial efficacy of simulated inhaled clofazimine versus oral clofazimine in combination with azithromycin and ethambutol in a hollow-fiber system
在空心纤维系统中，模拟吸入氯法齐明与口服氯法齐明联合阿奇霉素和乙胺丁醇的抗结核分枝杆菌疗效增强比较
Jelmer Raaijmakers and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf402, https://doi.org/10.1093/jac/dkaf402
21
Identification of antimicrobial resistance genes in Escherichia coli through network diffusion
通过网络扩散法鉴定大肠杆菌中的抗生素耐药基因
Anis Mansouri and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf404, https://doi.org/10.1093/jac/dkaf404
22
Preclinical evaluation of epetraborole in the hollow fibre system model of Mycobacterium abscessus lung disease
依培硼罗在脓肿分枝杆菌肺病空心纤维系统模型中的临床前评估
Sanjay Singh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf405, https://doi.org/10.1093/jac/dkaf405
23
The β-lactamase inhibitor concentration-dependent minimum inhibitory concentration (MICcBLI) as methodology to assess the pharmacokinetic/pharmacodynamic relationship of piperacillin/tazobactam for dosing optimization
β-内酰胺酶抑制剂浓度依赖性最低抑菌浓度（MICcBLI）作为评估哌拉西林/他唑巴坦药代动力学/药效动力学关系以优化给药的方法
Malin Andersson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf406, https://doi.org/10.1093/jac/dkaf406
24
Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction
解析铜绿假单胞菌AmpC诱导过程中青霉素结合蛋白、β-内酰胺酶活性和mRNA动态的三元关系
Maria Montaner and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf408, https://doi.org/10.1093/jac/dkaf408
25
Unnoticed spread of linear VanA-plasmids in vancomycin-variable Enterococcus faecium strains across different regions: a diagnostics challenge
不同地区万古霉素可变型粪肠球菌菌株中线性VanA质粒的未被察觉的传播：一项诊断挑战
Ana C Almeida-Santos and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf409, https://doi.org/10.1093/jac/dkaf409
26
Switching from etravirine to doravirine in virologically suppressed people with HIV: results from the French multicentre SWEED observational study
在病毒学抑制的HIV感染者中从依曲韦林切换至多拉韦林：法国多中心SWEED观察性研究的结果
Romain Palich and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf410, https://doi.org/10.1093/jac/dkaf410
27
HIV-1 drug resistance among pregnant and breastfeeding mothers and its association with paediatric HIV infections in the Dolutegravir era in Uganda
乌干达多替拉韦时代孕产妇及哺乳期母亲中HIV-1耐药情况及其与儿童HIV感染的关联
Anne Kapaata and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf411, https://doi.org/10.1093/jac/dkaf411
28
Outpatient antibiotic prescribing for medically attended respiratory syncytial virus, influenza, or human metapneumovirus illness among high-risk adults in rural Wisconsin, United States
美国威斯康星州农村地区高风险成人因呼吸道合胞病毒、流感或人偏肺病毒感染就诊时的门诊抗生素处方情况
Sarah C J Jorgensen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf412, https://doi.org/10.1093/jac/dkaf412
29
Omadacycline as a drug candidate for Mycobacterium avium infections: in vitro insights on single and combination therapies
奥马环素作为鸟分枝杆菌感染候选药物：单药及联合治疗的体外研究
Saskia E Mudde and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf413, https://doi.org/10.1093/jac/dkaf413
30
Post-pandemic trends in Streptococcus pneumoniae serotype epidemiology and antibiotic susceptibility in adults with invasive and non-invasive pneumococcal disease in the USA (2022–2023)
后疫情时代美国成人侵袭性与非侵袭性肺炎链球菌病血清型流行病学及抗生素敏感性趋势（2022-2023）
Mekki F Bensaci and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf414, https://doi.org/10.1093/jac/dkaf414
31
Benznidazole pharmacokinetics in patients with chronic Chagas disease: association with demographic factors and adverse drug reactions
慢性恰加斯病患者苯芴醇药代动力学：与人口统计学因素及药物不良反应的关联
Gabriel P E Silveira and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf416, https://doi.org/10.1093/jac/dkaf416
32
Acquired antimicrobial resistance genes in Bordetella Species: a global genomic analysis
博德特氏菌属中获得的抗菌药物耐药基因：全球基因组分析
Biao Tang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf418, https://doi.org/10.1093/jac/dkaf418
33
Machine learning for personalized antimicrobial susceptibility breakpoints: (Adaptive clinical breakpoint interpretation)
基于机器学习的个性化抗菌药物敏感性折点制定（自适应临床折点解释）
Yinzheng Zhong and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf419, https://doi.org/10.1093/jac/dkaf419
34
Multicentre investigation of Wickerhamomyces anomalus fungemia in India: emerging resistance and mechanistic insights
印度异常威克汉姆酵母菌血症的多中心研究：新发耐药性及机制洞察
Shristi Verma and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf420, https://doi.org/10.1093/jac/dkaf420
35
Reducing aztreonam/avibactam waste: insights from Monte Carlo simulations
减少氨曲南/阿维巴坦浪费：蒙特卡洛模拟的启示
Yeleen Fromage and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf421, https://doi.org/10.1093/jac/dkaf421
36
Nanoparticle-based co-delivery of ciprofloxacin and meropenem enhances synergistic activity against multidrug-resistant hypervirulent Klebsiella pneumoniae clinical isolates
基于纳米颗粒的环丙沙星与美罗培南共递送可增强对多重耐药高毒力肺炎克雷伯菌临床分离株的协同活性
Reham Mostafa and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf422, https://doi.org/10.1093/jac/dkaf422
37
Development of population pharmacokinetic models of total and free piperacillin in critically ill children and young adults for Monte Carlo simulations and model-informed precision dosing
危重症儿童及青年总游离哌拉西林群体药代动力学模型开发：用于蒙特卡洛模拟及模型引导的精准给药
Sonya Tang Girdwood and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf423, https://doi.org/10.1093/jac/dkaf423
38
Reaching the target: time and dose required to achieve target vancomycin plasma concentrations in admitted patients
达标分析：住院患者达到目标万古霉素血浆浓度所需的时间与剂量
W Töpfer and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf424, https://doi.org/10.1093/jac/dkaf424
39
Notable transmitted HIV drug resistance among people who inject drugs in Pakistan
巴基斯坦注射毒品人群中显著传播的HIV耐药性
Stephanie Melnychuk and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf425, https://doi.org/10.1093/jac/dkaf425
40
Synergistic but clinically unattainable: amoxicillin/ceftriaxone combination against ampicillin-susceptible Enterococcus faecium
协同但临床难以实现：阿莫西林/头孢曲松联合对氨苄西林敏感粪肠球菌的体外活性
Ahmed Ashrin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf426, https://doi.org/10.1093/jac/dkaf426
41
Pharmacodynamic studies of taniborbactam (VNRX-5133) combined with cefepime against β-lactamase–producing Gram-negative bacteria in a neutropenic murine thigh infection model
中性粒细胞减少小鼠大腿感染模型中他尼硼巴坦（VNRX-5133）联合头孢吡肟对产β-内酰胺酶革兰氏阴性菌的药效动力学研究
Panagiota-Christina Georgiou and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf431, https://doi.org/10.1093/jac/dkaf431
42
Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp.
非塞拉蒂亚属肠杆菌目细菌所致心内膜炎的流行病学及治疗
Clayton F Hausberger and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf432, https://doi.org/10.1093/jac/dkaf432
43
Enhanced activity of apramycin and apramycin-based combinations against Mycobacteroides abscessus
阿普拉霉素及其组合对脓肿分枝杆菌的增强活性
Yanqin Huang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf433, https://doi.org/10.1093/jac/dkaf433
44
Efflux-mediated multidrug resistance mechanism in Trichophyton indotineae and Trichophyton rubrum; role of ABC transporters and MFS gene
印度毛癣菌与红色毛癣菌中由ABC转运蛋白和MFS基因介导的流出泵型多重耐药机制
Dipika Shaw and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf434, https://doi.org/10.1093/jac/dkaf434
45
Sphingobacterium spp. as intrinsic producers of SPI Ambler class B metallo-β-lactamases
鞘氨醇杆菌属作为SPI Ambler B类金属β-内酰胺酶的固有产生者
Delphine Girlich and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf436, https://doi.org/10.1093/jac/dkaf436
46
Global phylogeography and genomic characterization of blaNDM-1-positive carbapenem-resistant Acinetobacter soli
blaNDM-1阳性碳青霉烯耐药溶胶阿卡净菌的全球系统发育地理学及基因组特征
Pengpeng Min and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf437, https://doi.org/10.1093/jac/dkaf437
47
Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients
血液透析患者潜伏性结核治疗中每月一次每日利福喷丁的药代动力学及耐受性
Thornthun Ueaphongsukkit and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf439, https://doi.org/10.1093/jac/dkaf439
48
In vitro susceptibility of cefepime-enmetazobactam, cefepime-taniborbactam and cefepime-zidebactam towards carbapenemase-producing Enterobacterales
头孢吡肟-恩美他唑巴坦、头孢吡肟-他尼硼巴坦及头孢吡肟-齐德巴坦对产碳青霉烯酶肠杆菌目的体外敏感性
Marion Dutkiewicz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf440, https://doi.org/10.1093/jac/dkaf440
49
In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates
舒巴坦/杜洛巴坦联合β-内酰胺类抗生素对澳大利亚脓肿分枝杆菌分离株的体外疗效
Kirby Patterson-Fahy and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf441, https://doi.org/10.1093/jac/dkaf441
50
Harnessing CRISPR–Cas9 and CRISPRi systems to reverse antibiotic resistance in a clinical multidrug-resistant Escherichia coli isolate
利用CRISPR-Cas9及CRISPRi系统逆转临床多重耐药大肠杆菌分离株的抗生素耐药性
Ruonan Zhao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf442, https://doi.org/10.1093/jac/dkaf442
51
Cotrimoxazole in the intensive care unit: an impossible task for the fixed association in real life?
重症监护室中复方磺胺甲噁唑的应用：固定组合在现实中的不可行性？
Manon Launay and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf443, https://doi.org/10.1093/jac/dkaf443
52
National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing
哥伦比亚全国代表性调查：基于下一代测序的抗逆转录病毒耐药相关突变分析
Ernesto Martínez-Buitrago and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf444, https://doi.org/10.1093/jac/dkaf444
53
A model-based comparison of dose reduction strategies for fixed-dose dolutegravir-containing regimens
基于模型的含固定剂量多替拉韦方案减量策略比较
Laura Dickinson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf445, https://doi.org/10.1093/jac/dkaf445
54
Therapeutic drug monitoring and target attainment of unbound flucloxacillin in hospitalized patients with measured MICs (FLUTE)
住院患者中游离氟氯西林的治疗药物监测及目标达成情况（基于实测最低抑菌浓度的FLUTE研究）
Pjotr P Temme and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf447, https://doi.org/10.1093/jac/dkaf447
55
Nirmatrelvir-ritonavir addition to acute care formulary: a retrospective, multi-centre evaluation of quantitative economic and qualitative clinical outcomes
奈玛特韦/利托那韦纳入急症治疗目录：一项多中心回顾性评估定量经济与定性临床结果的研究
Jose Valdes Ledesma and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf448, https://doi.org/10.1093/jac/dkaf448
56
Local antibiotic resistance surveillance in nursing homes using lot quality assurance sampling: a feasibility study
采用批量质量保证抽样法对养老院进行本地抗生素耐药性监测的可行性研究
Sacha Kuil and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf451, https://doi.org/10.1093/jac/dkaf451
57
High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021–24
2021-2024年，在世卫组织三个区域的八个世卫组织增强淋球菌抗菌药物监测计划国家中，新型抗菌药物吉皮达星对淋病奈瑟菌分离株的体外活性较高
Josefine Ahlstrand and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf452, https://doi.org/10.1093/jac/dkaf452
58
Despite increasing use of integrase inhibitors to treat HIV infection, resistance to this class remains stable
尽管整合酶抑制剂用于治疗HIV感染的使用量不断增加，但此类药物的耐药性仍保持稳定
Cathia Soulie and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf454, https://doi.org/10.1093/jac/dkaf454
59
Fine-needle aspiration in infected necrotizing pancreatitis in the delayed intervention era: a post hoc analysis of safety, microbiological yield and therapeutic implications
延迟干预时代感染性坏死性胰腺炎的细针穿刺抽吸术：安全性、微生物学检出率及治疗意义的事后分析
Hannah S Pauw and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf455, https://doi.org/10.1093/jac/dkaf455
60
β-Lactam dosing in critically ill children: predictors for target non-attainment
危重症儿童β-内酰胺类药物给药：未达目标浓度的预测因素
Stef Schouwenburg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf457, https://doi.org/10.1093/jac/dkaf457
61
Co-administration of triazoles with calcineurin or mammalian target of rapamycin inhibitors in solid organ transplant patients hospitalized with invasive aspergillosis
实体器官移植患者合并侵袭性曲霉病住院时三唑类药物与钙调磷酸酶抑制剂或哺乳动物雷帕霉素靶蛋白抑制剂的联合用药情况
Barbara Alexander and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf461, https://doi.org/10.1093/jac/dkaf461
62
In vitro selection of cefiderocol-resistant mutants in Acinetobacter baumannii harbouring the most common carbapenemase genes
携带最常见碳青霉烯酶基因的鲍曼不动杆菌中头孢地尔耐药突变体的体外筛选
Otávio Hallal Ferreira Raro and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf462, https://doi.org/10.1093/jac/dkaf462
63
Preventing resistance development in infections by OXA β-lactamase-producing Pseudomonas aeruginosa: correlating clinical outcomes with hollow-fibre model input
预防产OXA β-内酰胺酶铜绿假单胞菌感染耐药性的产生：将临床结局与中空纤维模型输入相关联
María M Montero and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf464, https://doi.org/10.1093/jac/dkaf464
64
A national pilot community pharmacy–led urinary tract infection service: clinical and patient-reported outcomes from 9077 consultations
全国社区药房主导的尿路感染服务试点项目：9077次咨询的临床结局和患者报告结局
Efi Mantzourani and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf466, https://doi.org/10.1093/jac/dkaf466
65
Towards enhanced translational value: preclinical drug activity testing against actively multiplying, nutrient-starved and pellicle biofilm-embedded Mycobacterium abscessus
提高转化价值：针对活跃增殖、营养匮乏和生物膜包裹的脓肿分枝杆菌进行临床前药物活性测试
Henriëtte M Meliefste and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf468, https://doi.org/10.1093/jac/dkaf468
Research Letters（研究快报）
66
Novel multiresistance transposon Tn7731 in bovine Pasteurella multocida from Germany
德国牛源多杀性巴氏杆菌中新型多重耐药转座子Tn7731
Henrike Krüger-Haker and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf336, https://doi.org/10.1093/jac/dkaf336
67
Efficacy of eravacycline in difficult-to-treat (DTR) Acinetobacter baumannii bacteraemia in ICU: a case report
厄他培南治疗重症监护病房难治性鲍曼不动杆菌菌血症的疗效：一例病例报告
Monica Melchio and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf347, https://doi.org/10.1093/jac/dkaf347
68
Possible increased risk of Epstein–Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients
来特莫韦暴露的造血细胞移植受者中EB病毒感染和移植后淋巴增殖性疾病风险可能增加
Jose F Camargo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf348, https://doi.org/10.1093/jac/dkaf348
69
Dalbavancin dosing in a severely underweight woman with prosthetic valve endocarditis: the critical role of proactive therapeutic drug monitoring
达巴万星在严重体重不足人工瓣膜心内膜炎女性患者中的给药：主动治疗药物监测的关键作用
Ambra Barco and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf365, https://doi.org/10.1093/jac/dkaf365
70
Cefazolin-induced seizures in a haemodialysis patient with elevated serum and cerebrospinal fluid concentrations: a case report
血液透析患者头孢唑林血清和脑脊液浓度升高诱发癫痫：一例病例报告
Kohei Hasegawa and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf373, https://doi.org/10.1093/jac/dkaf373
71
Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes
使用聚丙烯腈膜进行连续性肾脏替代治疗的患者中卡泊芬净药代动力学治疗监测的回顾性分析
Antoine Hérault and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf390, https://doi.org/10.1093/jac/dkaf390
72
Diffusion of OXA-48- and NDM-5-producing Klebsiella pneumoniae ST383 clone in Central Italy
产OXA-48和NDM-5的肺炎克雷伯菌ST383克隆在意大利中部的传播
Gloria D’Achille and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf397, https://doi.org/10.1093/jac/dkaf397
73
Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry
来那卡帕韦在病毒载量阳性且接受过大量抗逆转录病毒治疗的HIV感染者中的持久性：来自PRESTIGIO登记处的现实数据
Tommaso Clemente and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf415, https://doi.org/10.1093/jac/dkaf415
74
Co-carriage of the oxazolidinone resistance genes cfr and optrA in a linezolid-resistant Staphylococcus rostri isolate from a pig-farm worker
猪场工人利奈唑胺耐药猪鼻支原体分离株中噁唑烷酮类耐药基因cfr和optrA的共携带情况
Gi Yong Lee and Soo-Jin Yang
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf428, https://doi.org/10.1093/jac/dkaf428
75
Importance of reviewing the package insert from gradient strip manufacturers
梯度扩散法药敏纸片生产商说明书审阅的重要性
Mandy Wootton and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf429, https://doi.org/10.1093/jac/dkaf429
76
One resistance gene, many transposons: repeated formation of compound and pseudo-compound transposons carrying the aphA1 kanamycin and neomycin resistance gene
一个耐药基因，多个转座子：携带aphA1卡那霉素和新霉素耐药基因的复合及假复合转座子的重复形成
Christopher J Harmer and Ruth M Hall
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf450, https://doi.org/10.1093/jac/dkaf450
77
Absence of lymphogranuloma venereum among men who have sex with men on PrEP receiving doxycycline postexposure prophylaxis
接受暴露后多西环素预防性治疗的暴露前预防用药男男性行为者中未发现性病淋巴肉芽肿
Cristina Gómez-Ayerbe and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf456, https://doi.org/10.1093/jac/dkaf456
78
In vitro activity of gepotidacin against Chlamydia trachomatis
吉皮达星对沙眼衣原体的体外活性
Arabella Touati and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf460, https://doi.org/10.1093/jac/dkaf460
Journal of Antimicrobial Chemotherapy Volume 81, Issue 2抗菌化疗杂志 81卷 2期
https://academic.oup.com/jac/issue
Viewpoints（观点）
1
Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?
长效糖肽类：最需要它们的患者获取药物的障碍有哪些，如何克服？
Aleece MacPhail and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf471, https://doi.org/10.1093/jac/dkaf471
2
Redefining antifungal prophylaxis in acute leukaemia in the era of targeted therapies
靶向治疗时代急性白血病抗真菌预防的重新定义
Marcio Nucci and Johan Maertens
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag010, https://doi.org/10.1093/jac/dkag010
Reviews（综述）
3
Research progress on resistance mechanisms and clinical efficacy of tigecycline against Klebsiella pneumoniae
替加环素对肺炎克雷伯菌的耐药机制及临床疗效研究进展
Meilin Wu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf504, https://doi.org/10.1093/jac/dkaf504
4
Liposomal amphotericin B and renal safety: review of the evidence and clinical considerations
两性霉素B脂质体与肾脏安全性：证据回顾及临床考量
Johan Maertens and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf473, https://doi.org/10.1093/jac/dkaf473
5
Strategies for mitigating severe COVID-19 in patients with haematological malignancy during the omicron era
奥密克戎时代减轻血液系统恶性肿瘤患者严重新冠肺炎的策略
Keiji Okinaka and Joshua T Schiffer
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf489, https://doi.org/10.1093/jac/dkaf489
Systematic Reviews（系统综述）
6
Safety and efficacy of gepotidacin in urinary tract infection: a GRADE-assessed systematic review and meta-analysis
吉泊替达辛治疗尿路感染的安全性和有效性：一项基于GRADE评估的系统综述和荟萃分析
Taha Ibrahim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf469, https://doi.org/10.1093/jac/dkaf469
7
The emerging clinical relevance and antimicrobial resistance of Pluralibacter gergoviae: a systematic review
产吲哚金黄杆菌日益凸显的临床相关性和抗菌药物耐药性：一项系统综述
Bruna Abdul Ahad Saad and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf476, https://doi.org/10.1093/jac/dkaf476
8
A comprehensive analysis of the mutational landscape determining polymyxin resistance in Klebsiella pneumoniae
决定肺炎克雷伯菌多粘菌素耐药性的突变谱综合分析
Sambit Kumar Dwibedy and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf503, https://doi.org/10.1093/jac/dkaf503
9
Factors promoting or hindering self-administered outpatient parenteral antimicrobial therapy: a systematic literature review
促进或阻碍自我给药门诊静脉注射抗菌药物治疗的因素：一项系统文献综述
Hester H Stoorvogel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf490, https://doi.org/10.1093/jac/dkaf490
Original Research（论著）
10
Cefepime/enmetazobactam for Gram-negative periprosthetic joint infections? A randomized porcine study on target tissue pharmacokinetics
头孢吡肟/恩美唑巴坦治疗革兰氏阴性假体周围关节感染？一项关于猪的靶组织药代动力学的随机研究
M B D Nielsen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf487, https://doi.org/10.1093/jac/dkaf487
11
Impact of extracorporeal membrane oxygenation modes on voriconazole exposure in critically ill patients
体外膜肺氧合模式对危重患者伏立康唑暴露的影响
Xinrui Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf501, https://doi.org/10.1093/jac/dkaf501
12
Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants
基于模型通过成人和婴儿群体药代动力学-药效学模型评估VRC07-523LS在婴儿中的给药方案
Dustin Huynh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf449, https://doi.org/10.1093/jac/dkaf449
13
Antibiotic resistance of Pseudomonas aeruginosa strains—intracellular metabolomics analysis
铜绿假单胞菌菌株的抗生素耐药性——细胞内代谢组学分析
Karolina Anna Mielko-Niziałek and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf453, https://doi.org/10.1093/jac/dkaf453
14
In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates
头孢吡肟/齐多巴坦对舒巴坦/杜洛巴坦敏感和耐药鲍曼不动杆菌临床分离株的体外活性
Carlo Tascini and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf467, https://doi.org/10.1093/jac/dkaf467
15
Prevalence of macrolide resistance in Mycoplasma pneumoniae in The Netherlands
荷兰肺炎支原体大环内酯类抗生素耐药性的流行情况
Patrick D J Sturm and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf475, https://doi.org/10.1093/jac/dkaf475
16
Simulated lung exposure in pneumonia patients to evaluate the antibacterial capacity and resistance suppression of clinical tigecycline regimens against carbapenem-resistant
Acinetobacter baumannii
模拟肺炎患者肺部暴露情况以评估临床替加环素方案对碳青霉烯类耐药鲍曼不动杆菌的抗菌能力和耐药抑制作用
Xiaonan Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf477, https://doi.org/10.1093/jac/dkaf477
17
Enterococcus faecium harbouring vanA, optrA and cfr(D) on a linear plasmid in Canada: a CANWARD surveillance case
加拿大发现携带vanA、optrA和cfr(D)的粪肠球菌线性质粒：一项CANWARD监测病例
Melissa McCracken and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf478, https://doi.org/10.1093/jac/dkaf478
18
The effect of intrauterine exposure to aminoglycosides on neonatal hearing
宫内暴露于氨基糖苷类抗生素对新生儿听力的影响
Daniel Leshin-Carmel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf483, https://doi.org/10.1093/jac/dkaf483
19
Ceftazidime/avibactam: a potent arsenal against multidrug-resistant Pseudomonas aeruginosa-unveiling in vitro and in vivo strategies
头孢他啶/阿维巴坦：对抗多重耐药铜绿假单胞菌的有力武器——揭示体内外策略
Jiaju Zhuo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf495, https://doi.org/10.1093/jac/dkaf495
20
Comparison of disk diffusion, MIC test strip and broth microdilution for eravacycline susceptibility testing of 422 Staphylococcus aureus isolates using ChinaCAST breakpoints
采用中国CAST折点，比较422株金黄色葡萄球菌对依拉环素的纸片扩散法、最低抑菌浓度测试条法和肉汤微量稀释法的敏感性测试结果
Xinying Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf502, https://doi.org/10.1093/jac/dkaf502
21
Penetration of daptomycin in cerebrospinal fluid during pneumococcal meningitis
肺炎链球菌性脑膜炎期间达托霉素在脑脊液中的渗透情况
Pascal Chavanet and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf474, https://doi.org/10.1093/jac/dkaf474
22
Rapid molecular diagnostics for detection of extensively drug-resistant Salmonella Typhi
用于检测广泛耐药伤寒沙门菌的快速分子诊断技术
Emma L Sweeney and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf481, https://doi.org/10.1093/jac/dkaf481
23
Gender inequality and antibiotic consumption: analysis of pharmaceutical sales data from 70 countries, 2000–22
性别不平等与抗生素消费：基于2000 - 2022年70个国家药品销售数据的分析
Deepshikha Batheja and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag002, https://doi.org/10.1093/jac/dkag002
24
Real-world evaluation of isavuconazole in children with cancer
伊沙康唑在儿童癌症患者中的现实应用评估
Janine Nijhuis and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf485, https://doi.org/10.1093/jac/dkaf485
25
Assessing antimicrobial susceptibility testing guideline adherence by laboratories providing bacteriology services in Ghana: a pilot study
加纳提供细菌学服务的实验室对抗菌药物敏感性试验指南依从性的评估：一项试点研究
Joseph Elikem Efui Acolatse and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag003, https://doi.org/10.1093/jac/dkag003
26
Resistance to second-generation integrase inhibitors in people with HIV following treatment failure on dolutegravir- or bictegravir-based ART in Taiwan
台湾地区基于多替拉韦或比克替拉韦的抗逆转录病毒治疗失败后，HIV感染者对第二代整合酶抑制剂的耐药性
Guan-Jhou Chen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf488, https://doi.org/10.1093/jac/dkaf488
27
In vitro activity of gepotidacin against a challenging panel of multidrug-resistant Neisseria gonorrhoeae isolates
吉泊西汀对一组具有挑战性的多重耐药淋病奈瑟菌分离株的体外活性
Michelle Jayne Cole and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag001, https://doi.org/10.1093/jac/dkag001
28
A disproportionality analysis of adverse events associated with omadacycline based on the FDA adverse event reporting system database
基于美国食品药品监督管理局（FDA）不良事件报告系统数据库的奥马环素相关不良事件比例失衡分析
Ye-Lei Zhao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag006, https://doi.org/10.1093/jac/dkag006
29
Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis
基于体重范围的口服异速缩放米替福新给药方案在儿童内脏利什曼病患者中的简化应用
Andres Mazariegos Herrera and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag014, https://doi.org/10.1093/jac/dkag014
30
evelopment of a capability framework for antimicrobial stewardship specialist health professionals working in the NHS in England: utilizing Delphi methodology
运用德尔菲法为在英国国家医疗服务体系（NHS）中工作的抗菌药物管理专业人员制定能力框架
Ryan A Hamilton and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf438, https://doi.org/10.1093/jac/dkaf438
31
First characterization of insertions in the HIV-1 integrase-coding region from people with HIV
首次对来自艾滋病病毒感染者的HIV-1整合酶编码区插入情况进行特征分析
Nhat Quang Tu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf491, https://doi.org/10.1093/jac/dkaf491
32
Development of an impedance-based fast antimicrobial susceptibility test for Neisseria gonorrhoeae
开发一种基于阻抗的淋病奈瑟菌快速抗菌药物敏感性检测方法
Caitlin N Daniels and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf493, https://doi.org/10.1093/jac/dkaf493
33
Juvenile toxicity and developmental safety of Zintrodiazine, a novel antimalarial candidate, in Wistar rats
新型抗疟候选药物Zintrodiazine在Wistar大鼠中的幼年毒性和发育安全性研究
Hitesh A Kadu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag008, https://doi.org/10.1093/jac/dkag008
34
Do the redefined EUCAST susceptibility categories warrant adjustment of paediatric antibiotic dosages? Pragmatic physiologically based pharmacokinetic modelling of four commonly used agents
欧洲抗微生物药物敏感性试验委员会（EUCAST）重新定义的敏感性分类是否需要调整儿童抗生素剂量？——对四种常用药物的实用生理药代动力学建模研究
Marika A de Hoop-Sommen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf463, https://doi.org/10.1093/jac/dkaf463
35
Exploring the opportunity for therapeutic drug monitoring (TDM) and precision dose antimicrobials in an outpatient antimicrobial therapy (OPAT) service: a prospective observational study
门诊抗菌治疗（OPAT）服务中开展治疗药物监测（TDM）和精准剂量抗菌治疗的机遇：一项前瞻性观察研究
R C Wilson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf484, https://doi.org/10.1093/jac/dkaf484
36
Impact of sex, age and body composition on rilpivirine and cabotegravir trough concentrations in people with HIV receiving long-acting injectable antiretroviral therapy
性别、年龄和身体成分对接受长效注射用抗逆转录病毒治疗的HIV感染者利匹韦林和卡博特韦谷浓度的影响
Maria Vittoria Cossu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag024, https://doi.org/10.1093/jac/dkag024
37
Pharmacokinetics of cefiderocol during prolonged intermittent kidney replacement therapy in two patients with septic shock
头孢地尔在两例感染性休克患者长时间间歇性肾脏替代治疗期间的药代动力学
Julius J Schmidt and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf496, https://doi.org/10.1093/jac/dkaf496
38
Understanding mechanisms of reduced cefiderocol susceptibility in pvdS and fecI mutants of Pseudomonas aeruginosa
了解铜绿假单胞菌pvdS和fecI突变体对头孢地尔敏感性降低的机制
Yoshinori Yamano and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag004, https://doi.org/10.1093/jac/dkag004
39
Biomarker-informed PBPK modelling of meropenem in paediatric severe pneumonia: implications for target-site PK/PD
基于生物标志物的美罗培南在儿童重症肺炎中的生理药动学模型构建：对靶部位药代动力学/药效学的影响
Yao Liu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf500, https://doi.org/10.1093/jac/dkaf500
40
Evaluating hypoalbuminaemia thresholds associated with delayed blood sterilization among patients receiving cefazolin or antistaphylococcal penicillins for MSSA bacteraemia
评估接受头孢唑林或抗葡萄球菌青霉素治疗甲氧西林敏感金黄色葡萄球菌（MSSA）菌血症患者中，与血液延迟灭菌相关的低白蛋白血症阈值
Sunish Shah and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf498, https://doi.org/10.1093/jac/dkaf498
Research Letters（研究快讯）
41
False-negative result in fourth-generation HIV screening tests after weak detection of p24 antigen in the context of inappropriate post-exposure prophylaxis use: a case report
不当使用暴露后预防用药导致第四代HIV筛查试验p24抗原弱检出后出现假阴性结果：一例病例报告
J Kimmerlin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf459, https://doi.org/10.1093/jac/dkaf459
42
Proposal for the nomenclature of tmexCD-toprJ-like gene clusters
关于tmexCD-toprJ样基因簇命名的建议
Chengzhen Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf482, https://doi.org/10.1093/jac/dkaf482
43
IS26-mediated chromosomal integration of virulence plasmid fragments in ST2237 carbapenem-resistant Klebsiella pneumoniae
IS26介导的毒力质粒片段在ST2237型碳青霉烯耐药肺炎克雷伯菌染色体中的整合
Yan Li and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag018, https://doi.org/10.1093/jac/dkag018
Letter to the Editor（致编辑的信）
44
Comment on: Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes
对“采用聚丙烯腈膜对接受连续性肾脏替代治疗的患者进行卡泊芬净药代动力学监测的回顾性分析”的评论
Gwénola Marais and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf465, https://doi.org/10.1093/jac/dkaf465
45
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy-right-to-reply
意大利米兰地区使用多西环素暴露后预防（DoxyPEP）人群中，用于治疗细菌性传播感染的抗菌药物使用情况——回应说明
Angelo Roberto Raccagni and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag027, https://doi.org/10.1093/jac/dkag027
ACKNOWLEDGEMENT OF REFEREES（鸣谢审稿专家）
46
Acknowledgement of Referees
鸣谢审稿专家
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf417, https://doi.org/10.1093/jac/dkaf417
CORRECTION（更正）
47
Correction to: Comment on: Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial
更正：关于Evusheld在感染奥密克戎变异株前或奥密克戎变异株的新冠住院患者中的抗病毒效果：对随机DisCoVeRy试验的建模分析的评论
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf492, https://doi.org/10.1093/jac/dkaf492
Journal of Antimicrobial Chemotherapy Volume 81, Issue 3抗菌化疗杂志 81卷 3期
https://academic.oup.com/jac/issue
REVIEW（综述）
1
Closing the PrEP access gap in Europe: a strategic framework for equity and innovation among difficult-to-reach populations
缩小欧洲暴露前预防获取差距：面向难以触及（PrEP）人群的公平与创新战略框架
Josep M Llibre and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag052, https://doi.org/10.1093/jac/dkag052
2
Precision dosing of systemic antifungals in adults: therapeutic drug monitoring, empiric dose optimization and barriers to implementation
成人全身性抗真菌药物的精准给药：治疗药物监测、经验性剂量优化及实施障碍
Daniel B Chastain and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag055, https://doi.org/10.1093/jac/dkag055
3
Bacterial DNA topoisomerase IV and DNA gyrase inhibitors: history of the quinolones, their clinical usage and potential alternatives for the future
细菌DNA拓扑异构酶IV和DNA旋转酶抑制剂：喹诺酮类药物的历史、临床应用及未来潜在替代方案
Daisuke Fukuda and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag054, https://doi.org/10.1093/jac/dkag054
4
Combating multidrug-resistant Klebsiella pneumoniae: current therapeutic regimens and future directions
应对多重耐药肺炎克雷伯菌：当前治疗方案与未来方向
Robiul Islam and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag064, https://doi.org/10.1093/jac/dkag064
SYSTEMATIC REVIEW（系统综述）
5
Global and regional prevalence of metallo-β-lactamases in carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis
耐碳青霉烯类鲍曼不动杆菌中金属β-内酰胺酶的全球和区域流行情况：一项系统综述和荟萃分析
Stamatis Karakonstantis and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag037, https://doi.org/10.1093/jac/dkag037
Original Research（论著）
6
The effect of oral ciprofloxacin at conventional doses on the QT interval in a tertiary outpatient setting
三级门诊常规剂量口服环丙沙星对患者QT间期的影响
Weber Liu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag020, https://doi.org/10.1093/jac/dkag020
7
Bictegravir concentrations in breastmilk of healthy, lactating women without HIV
未感染人类免疫缺陷病毒（HIV）的健康哺乳期女性乳汁中的比克替拉韦浓度
L C van der Wekken-Pas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag022, https://doi.org/10.1093/jac/dkag022
8
Management and outcomes of Stenotrophomonas maltophilia recovered from deep-site clinical specimens: a bicentric retrospective cohort study
从深部部位临床标本中分离出的嗜麦芽窄食单胞菌的治疗及转归：一项双中心回顾性队列研究
Anastasia Saade and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag021, https://doi.org/10.1093/jac/dkag021
9
Development of a risk prediction model for vancomycin-associated acute kidney injury: a multicentre retrospective study
万古霉素相关急性肾损伤风险预测模型的建立：一项多中心回顾性研究
Tomoyuki Ishigo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag012, https://doi.org/10.1093/jac/dkag012
10
Cooperation between HIV-1 integrase natural polymorphism K156N and 3′PPT mutations in dolutegravir monotherapy failure
HIV-1 整合酶天然多态性 K156N 与 3′PPT 突变在多替拉韦单药治疗失败中的协同作用
Jolieke A T van Osch and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag033, https://doi.org/10.1093/jac/dkag033
11
Impact of body mass index and serum albumin levels on isavuconazole plasma concentrations in patients with haematological malignancies
体重指数和血清白蛋白水平对血液系统恶性肿瘤患者艾沙康唑血浆浓度的影响
Jie Gao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag032, https://doi.org/10.1093/jac/dkag032
12
Pharmacokinetics of cefotaxime and its metabolite desacetyl-cefotaxime to optimize dosing in critically ill children and children with sickle cell disease
用以优化危重症儿童和镰状细胞病儿童给药剂量的头孢噻肟及其代谢产物去乙酰头孢噻肟的药代动力学研究
Seef Abdalla and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag019, https://doi.org/10.1093/jac/dkag019
13
Summary of ceftriaxone-resistant Neisseria gonorrhoeae in Canada, 2017–24
2017 - 2024年加拿大头孢曲松耐药淋病奈瑟菌情况汇总
Robyn Thorington and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag007, https://doi.org/10.1093/jac/dkag007
14
Improving perioperative prophylactic antibiotic prescribing using a novel decision-support tool
使用新型决策支持工具改进围手术期预防性抗生素处方
Mark Mcintyre and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag015, https://doi.org/10.1093/jac/dkag015
15
Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study
针对产超广谱AmpC酶的阴沟肠杆菌复合群和产气克雷伯菌临床分离株，比较已上市与新一代β-内酰胺类抗生素的抗菌活性：一项多中心研究
Ángel Rodríguez-Villodres and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag034, https://doi.org/10.1093/jac/dkag034
16
Impact of eravacycline on fibrinogen
依拉环素对纤维蛋白原的影响
Emily Stevenson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag030, https://doi.org/10.1093/jac/dkag030
17
Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime–avibactam in a case series of orthotopic liver transplant recipients
原位肝移植受者连续输注头孢他啶-阿维巴坦的药代动力学/药效学胆系分析：一项病例系列研究
Milo Gatti and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag009, https://doi.org/10.1093/jac/dkag009
18
Autoaggregation-associated carbapenem tolerance mediated by mrkH inactivation identified from a cohort of Klebsiella pneumoniae species complex clinical isolates
从肺炎克雷伯菌复合群临床分离株队列中鉴定出由mrkH失活介导的与自动聚集相关的碳青霉烯耐受性
Natsuki Yamanaka and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag017, https://doi.org/10.1093/jac/dkag017
19
In vitro activity of double and triple antimicrobial combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm
双联和三联抗菌药物组合对碳青霉烯耐药铜绿假单胞菌生物膜的体外活性研究
Si-Ho Kim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag031, https://doi.org/10.1093/jac/dkag031
20
LYSC98 as a novel vancomycin-derived agent effective against antibiotic-resistant pathogens in tolerant state
LYSC98作为一种新型万古霉素衍生物，对耐受状态下的耐药病原体有效
Xing Xia and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag036, https://doi.org/10.1093/jac/dkag036
21
HBV status modulates transaminase decrease after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV
HIV感染者从富马酸替诺福韦二吡呋酯切换为丙酚替诺福韦后，HBV状态对转氨酶下降的调节作用
Giuseppe Lapadula and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag045, https://doi.org/10.1093/jac/dkag045
22
Pharmacokinetics of colistin in adult critically ill patients in South Africa
南非成人危重症患者中多黏菌素的药代动力学研究
Veshni Pillay-Fuentes Lorente and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag011, https://doi.org/10.1093/jac/dkag011
23
Antifungal susceptibility surveillance of clinical moulds to olorofim, manogepix, amphotericin B, triazoles and echinocandins at 10 tertiary hospitals in China (2019–24)
2019 - 2024年中国10家三级医院临床霉菌对奥罗芬净、马诺盖匹克斯、两性霉素B、三唑类和棘白菌素类抗真菌药的敏感性监测
Su Chen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag016, https://doi.org/10.1093/jac/dkag016
24
Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study
短周期每周三日依非韦伦/恩曲他滨/富马酸替诺福韦二吡呋酯疗法：一项为期七年的延长研究
Beatriz Borjabad and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag040, https://doi.org/10.1093/jac/dkag040
25
Risk of hypertension in people with HIV in the USA initiating modern antiretroviral regimens: pooled analysis of blood pressure data from five clinical trials
美国感染HIV者启动现代抗逆转录病毒治疗方案后患高血压的风险：五项临床试验血压数据汇总分析
Priscilla Y Hsue and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag005, https://doi.org/10.1093/jac/dkag005
26
Real-world drug monitoring of dalbavancin using a three-dose regimen of 1500mg at days 1, 15 and 43 in bone and joint or cardiovascular infection
采用第1、15和43天各1500毫克的三剂量方案对达巴万星（Dalbavancin）在骨关节或心血管感染治疗中的实际药物监测研究
Thomas Lin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag039, https://doi.org/10.1093/jac/dkag039
27
Nationwide patterns of HIV drug resistance and high viral load in Sub-Saharan African countries
撒哈拉以南非洲国家全国范围内的HIV耐药及高病毒载量模式
Abubaker Ibrahim Elbur and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf497, https://doi.org/10.1093/jac/dkaf497
28
Risk factors for suboptimal target attainment of commonly used ß-lactam antibiotics in older adults: a prospective cohort study
老年人常用β-内酰胺类抗生素未达最佳治疗目标的风险因素：一项前瞻性队列研究
Arnaud De Clercq and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag048, https://doi.org/10.1093/jac/dkag048
29
Physiologically based pharmacokinetic modelling to optimize dosing regimen of biapenem in renal impairment and elderly populations
基于生理的药代动力学模型优化肾功能不全及老年人群比阿培南给药方案
Wenyan Li and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf499, https://doi.org/10.1093/jac/dkaf499
30
Early targeted therapy guided by rapid phenotypic antimicrobial susceptibility testing in critically ill patients with Gram-negative bacterial bloodstream infections: a retrospective cohort study
快速表型抗菌药物敏感性试验指导下的早期目标性治疗对革兰氏阴性菌血流感染危重患者的效果：一项回顾性队列研究
Salvatore Rotundo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag056, https://doi.org/10.1093/jac/dkag056
31
Impact of COVID-19-related healthcare changes on antibiotic resistance in clinical Escherichia coli isolates: interrupted time series analyses in Scotland, UK
与新冠肺炎相关的医疗变化对英国苏格兰地区临床大肠杆菌分离株抗生素耐药性的影响：中断时间序列分析
Laura Ciaccio and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag049, https://doi.org/10.1093/jac/dkag049
32
Multicentre evaluation of teicoplanin prescribing and monitoring in the UK and Ireland: the TUcK–SHOP study
英国和爱尔兰替考拉宁处方与监测的多中心评估：TUcK–SHOP研究
Stephen Hughes and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag038, https://doi.org/10.1093/jac/dkag038
33
Diabetes and risk of significant fibrosis in adults with HIV and metabolic dysfunction-associated steatotic liver disease: a prospective cohort study
糖尿病与HIV合并代谢功能障碍相关脂肪性肝病成人患者发生显著肝纤维化的风险：一项前瞻性队列研究
Win Min Han and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag053, https://doi.org/10.1093/jac/dkag053
34
A pharmacovigilance analysis of carbapenem-related utilizing the FDA adverse event reporting system (FAERS) database from 2013 to 2025
基于美国食品药品监督管理局不良事件报告系统（FAERS）数据库2013 - 2025年数据的碳青霉烯类相关药物警戒分析
Connor Frey and Parham Elmi
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag060, https://doi.org/10.1093/jac/dkag060
35
Effects of extracorporeal membrane oxygenation on the pharmacokinetics and tissue penetration rates of vancomycin and linezolid: data from Landrace pigs
体外膜肺氧合对万古霉素和利奈唑胺药代动力学及组织穿透率的影响：来自长白猪的数据
Huifang Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag063, https://doi.org/10.1093/jac/dkag063
36
Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomes
在既往存在耐药突变的人类免疫缺陷病毒（HIV）感染者中换用比克替拉韦/恩曲他滨/丙酚替诺福韦治疗。来自意大利ARCA队列的数据：BIC-BARRIER研究。比克替拉韦/恩曲他滨/丙酚替诺福韦（B/F/TAF）换药方案：耐药突变与治疗结果
Laura Pezzati and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag035, https://doi.org/10.1093/jac/dkag035
37
A two-stage diagnostic model for discriminating and assessing risk of meropenem heteroresistance in Pseudomonas aeruginosa
用于鉴别和评估铜绿假单胞菌对美罗培南异质性耐药风险的二阶段诊断模型
Yali Fan and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag061, https://doi.org/10.1093/jac/dkag061
38
Microdialysis assessment of gentamicin for second-line antimicrobial prophylaxis in abdominal surgery
微透析评估庆大霉素在腹部手术中作为二线抗菌预防药物的效果
Quentin Saint-Genis and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag071, https://doi.org/10.1093/jac/dkag071
39
Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers
伏立康唑药代动力学及肝毒性的遗传和临床预测因素：聚焦于CYP2C19正常代谢型和中间代谢型
Hui Li and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag065, https://doi.org/10.1093/jac/dkag065
40
Stakeholder perspectives on the offer and acceptance of self-administration of outpatient parenteral antimicrobial therapy: a qualitative study
利益相关者对提供和接受门诊患者自行注射抗菌药物治疗的看法：一项定性研究
Hester H Stoorvogel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag068, https://doi.org/10.1093/jac/dkag068
41
Is current guidance for cloxacillin prophylaxis dosages in hip and knee arthroplasty adequate? Evidence from a prospective Swedish cohort
当前髋关节和膝关节置换术中氯唑西林预防性用药剂量指南是否充分？来自一项前瞻性瑞典队列研究的证据
Katja Wallander and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag067, https://doi.org/10.1093/jac/dkag067
42
Effect of pretreatment HIV drug resistance on mortality, attrition and viral suppression in patients initiating antiretroviral therapy and genetic transmission network: an observational cohort study in Southwest China
治疗前HIV药物耐药性对开始接受抗逆转录病毒治疗患者的死亡率、失访率和病毒抑制率的影响以及遗传传播网络：中国西南地区一项观察性队列研究
Litai Qin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag073, https://doi.org/10.1093/jac/dkag073
RESEARCH LETTER（研究快讯）
43
Varicella and varicella zoster virus meningoencephalitis in a diffuse large B-cell lymphoma patient after chimeric antigen receptor-T-cell therapy
嵌合抗原受体T细胞疗法后，弥漫性大B细胞淋巴瘤患者发生水痘及水痘-带状疱疹病毒脑膜脑炎
Yan Feng and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag041, https://doi.org/10.1093/jac/dkag041
44
The ‘double hit’ on dalbavancin pharmacokinetics: hypertriglyceridaemia and augmented renal clearance in a child with glycogen storage disease type Ib
糖原累积病Ib型患儿中，高甘油三酯血症和肾清除率增加对达巴万星药代动力学的“双重打击”
Bianca Monti and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag028, https://doi.org/10.1093/jac/dkag028
45
Tn7860, a novel chromosomal pseudo-compound transposon carrying the OptrA gene in Enterococcus faecalis
Tn7860，粪肠球菌中携带OptrA基因的一种新型染色体假复合转座子
Francesca Romana Massacci and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag046, https://doi.org/10.1093/jac/dkag046
46
HBV reactivation after switching to cabotegravir plus rilpivirine therapy among people living with HIV: do not forget the reservoir
HIV感染者换用卡博特韦（cabotegravir）联合利匹韦林（rilpivirine）治疗后乙肝病毒再激活：切勿忽视病毒储存库
Rémi Rouget and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag050, https://doi.org/10.1093/jac/dkag050
47
An inoperable mediastinal infection involving vascular graft treated with weekly oritavancin as chronic suppressive therapy. A case report with pharmacokinetic data
一例涉及血管移植物的无法手术的纵隔感染，采用每周一次的奥利万星作为慢性抑制疗法。附药代动力学数据的病例报告
Pierangelo Chinello and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag013, https://doi.org/10.1093/jac/dkag013
48
Evaluation of the Carbapenemase Detection Kit (Colloidal Gold; Macro & Micro Test): a new immunochromatographic assay for rapid detection of carbapenemases in Enterobacterales
碳青霉烯酶检测试剂盒（胶体金法；宏基因与微基因检测法）评估：一种用于快速检测肠杆菌目细菌中碳青霉烯酶的新型免疫层析法
Hippolyte De Swardt and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag066, https://doi.org/10.1093/jac/dkag066
49
Cefalexin use in UK acute pyelonephritis practice: unaddressed challenges in dosing, breakpoints and clinical evidence
头孢氨苄在英国急性肾盂肾炎治疗中的应用：给药、断点和临床证据方面尚未解决的挑战
Stephen Hughes and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag051, https://doi.org/10.1093/jac/dkag051
LETTERS TO THE EDITOR（致编辑的信）
50
Comment on: Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy
评论：意大利米兰多西环素暴露后预防（DoxyPEP）使用者中用于治疗细菌性性传播感染的抗菌药物使用情况
Chris Kenyon
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag025, https://doi.org/10.1093/jac/dkag025
51
Possible increased risk of Epstein–Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients: right-to-reply
来特莫韦暴露的造血细胞移植受者发生EB病毒（EBV）感染和移植后淋巴增殖性疾病（PTLD）的风险可能增加：答复权
Jose F Camargo and Anthony D Anderson
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag043, https://doi.org/10.1093/jac/dkag043
52
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy—right-to-reply
意大利米兰市使用多西环素暴露后预防（DoxyPEP）人群中，用于治疗细菌性性传播感染的抗菌药物使用情况——答复权声明
Angelo Roberto Raccagni and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag026, https://doi.org/10.1093/jac/dkag026
53
Comment on: Artificial intelligence for improving decision-making in bacterial infection management
述评：人工智能在细菌感染管理决策中的优化作用
Daniele Roberto Giacobbe
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag078, https://doi.org/10.1093/jac/dkag078
CORRECTION（更正）
54
Correction to: Bayesian estimation of the prevalence of antimicrobial resistance: a mathematical modelling study
更正：抗菌药物耐药性流行率的贝叶斯估计：一项数学建模研究
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf494, https://doi.org/10.1093/jac/dkaf494
55
Correction to: National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing
更正：哥伦比亚具有全国代表性的治疗前HIV耐药性调查：使用下一代测序技术分析抗逆转录病毒耐药相关突变
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag057, https://doi.org/10.1093/jac/dkag057
Journal of Antimicrobial Chemotherapy Volume 81, Issue 4抗菌化疗杂志81卷 4期
https://academic.oup.com/jac/issue
50TH ANNIVERSARY COLLECTION（50周年纪念合集）
GARROD LECTURE（加罗德讲座）
1
Garrod lecture: achieving the UNGA AMR mortality reduction goals
加罗德讲座：实现联合国大会抗菌药物耐药性死亡率降低目标
Ramanan Laxminarayan
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag082, https://doi.org/10.1093/jac/dkag082
REVIEW（综述）
2
25 years of improvement in mortality in invasive aspergillosis in haematology patients: will it be sustained or is it under threat?
侵袭性曲霉病血液病患者25年死亡率改善情况：这种改善能否持续，还是正受到威胁？
Johan A Maertens and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag077, https://doi.org/10.1093/jac/dkag077
3
A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 2: from molecule to confirmed hit
针对锥虫病的从高质量潜在客户和药物开发候选者出发的战略发现路线图。第二部分：从分子到确证活性分子
Sarah Hendrickx and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag110, https://doi.org/10.1093/jac/dkag110
VIRTUAL ROUNDTABLE（虚拟圆桌会议）
4
Diagnosis and risk factors for invasive mould disease—a round table discussion on directing antifungal therapy according to the available evidence
侵袭性霉菌病的诊断与危险因素——根据现有证据指导抗真菌治疗的圆桌讨论
Ana Alastruey-Izqueirdo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag062, https://doi.org/10.1093/jac/dkag062
EDITORIALS, MESSAGES FROM THE OUTGOING AND INCOMING EDITORS-IN-CHIEF（社论、离任与就任主编寄语）
5
Message from the incoming Editor-in-Chief of JAC
《抗菌化疗杂志》就任主编寄语
Monica A Slavin
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf479, https://doi.org/10.1093/jac/dkaf479
6
Message from the outgoing Editor-in-Chief
离任主编寄语
J Peter Donnelly
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf480, https://doi.org/10.1093/jac/dkaf480
REVIEW（综述）
7
Experimental biofilm models for pharmacokinetic and pharmacodynamic investigations: bridging in vitro, ex vivo and in vivo systems
用于药代动力学和药效学研究的实验性生物膜模型：连接体外、离体和体内系统
Stephanie Supparitsch and Markus Zeitlinger
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag091, https://doi.org/10.1093/jac/dkag091
8
Antimicrobial therapy for infected necrotizing pancreatitis: microbiology, antimicrobial resistance and pharmacokinetics
感染性坏死性胰腺炎的抗菌治疗：微生物学、抗菌药物耐药性及药代动力学
Hannah S Pauw and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag092, https://doi.org/10.1093/jac/dkag092
9
Continuous linezolid infusion: the new way to dose, the old risks to fear
持续输注利奈唑胺：新的给药方式，仍需警惕旧有风险
Daniel Muñoz-Pichuante and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag100, https://doi.org/10.1093/jac/dkag100
10
Alignment of national standard treatment guidelines with WHO AWaRe recommendations for adult primary care infectious diseases: implications for antimicrobial stewardship
将国家标准治疗指南与世卫组织（WHO）针对成人初级保健传染病的“慎用、监测、备用”（AWaRe）推荐意见相统一：对抗菌药物管理的影响
Huda Arooj and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag099, https://doi.org/10.1093/jac/dkag099
SYSTEMATIC REVIEW（系统综述）
11
Healthcare providers’ experiences in caring for MDRO carriers with a focus on the moral dimensions of care: a systematic review
医疗服务提供者护理多重耐药菌（MDRO）携带者的经历——聚焦护理中的道德维度：一项系统综述
Carlijn Damsté and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag059, https://doi.org/10.1093/jac/dkag059
12
Extrapolation of oritavancin PK/PD targets to inform therapeutic drug monitoring: a systematic review
奥利他万星药代动力学/药效学目标的外推用以指导治疗药物监测：一项系统综述
Giammarco Baiardi and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag117, https://doi.org/10.1093/jac/dkag117
ORIGINAL RESEARCH（论著）
13
Beyond plasma: defining the translation value of epithelial lining fluid exposure profiles for the treatment of pneumonia
超越血浆：明确上皮衬里液暴露谱对肺炎治疗的转化价值
Yakun Fu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf458, https://doi.org/10.1093/jac/dkaf458
14
Impact of loading dose β-lactam therapy on outcomes of KPC-producing Klebsiella pneumoniae bloodstream infections in non-ICU patients: a real world study
负荷剂量β-内酰胺类药物治疗非重症监护病房患者产KPC肺炎克雷伯菌血流感染的疗效影响：一项现实研究
Luisa Frallonardo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag087, https://doi.org/10.1093/jac/dkag087
15
Rezafungin exhibits anti-biofilm properties against fungal biofilms in vitro
雷扎芬净在体外对真菌生物膜表现出抗生物膜特性
Hafsa Abduljalil and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag058, https://doi.org/10.1093/jac/dkag058
16
Vancomycin resistance predicts increased mortality in patients with Enterococcus faecium bloodstream infections: a six-year experience at a large tertiary care Italian hospital
万古霉素耐药性可预测屎肠球菌血流感染患者死亡率增加：意大利一家大型三级医院六年来的经验
Lucia Graziani and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag069, https://doi.org/10.1093/jac/dkag069
17
Fluoroquinolones and the risk of panic attacks: a systematic review and disproportionality analysis using individual case safety reports from the FDA Adverse Event Reporting System (FAERS) database
氟喹诺酮类药物与惊恐发作风险：基于美国食品药品监督管理局不良事件报告系统（FAERS）数据库中个体病例安全报告的系统综述和比例失衡分析
Keeirah Hiertika Raguram and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag083, https://doi.org/10.1093/jac/dkag083
18
Cefuroxime concentrations in facial artery musculomucosal flap, buccal submucosa, subcutaneous tissue, and plasma following bolus or continuous infusion in patients undergoing oral cancer resection: a randomized clinical microdialysis study
在接受口腔癌切除术的患者中，采用随机临床微透析研究，探究头孢呋辛在面动脉肌黏膜瓣、颊黏膜下层、皮下组织和血浆中的浓度（团注或持续输注后）
Johanne Ravn Hansen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag085, https://doi.org/10.1093/jac/dkag085
19
Infection point of care tests bridge the experience gap of antibiotic STOP decisions: clinicians versus students
感染即时检测可弥补抗生素停药决策方面的经验差距：临床医生与学生对比
Archit Singhal and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf486, https://doi.org/10.1093/jac/dkaf486
20
Functional analysis of a novel macrolide–lincosamide resistance gene erm(57) in Cutibacterium avidum
痤疮丙酸杆菌中一种新型大环内酯 - 林可酰胺类耐药基因erm(57)的功能分析
Juri Koizumi and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag029, https://doi.org/10.1093/jac/dkag029
21
HIV drug resistance amongst children and adolescents with viraemia in Lesotho and Tanzania: a nested analysis in the GIVE MOVE trial
莱索托和坦桑尼亚病毒血症儿童及青少年中的HIV耐药性：GIVE MOVE试验的嵌套分析
Christof Manuel Schönenberger and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag070, https://doi.org/10.1093/jac/dkag070
22
Identification and assessment of paediatric cefepime-induced neurotoxicity in a retrospective cohort of paediatric intensive care patients
在儿科重症监护患者回顾性队列中识别和评估儿科头孢吡肟诱导的神经毒性
Kathryn Pavia and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag075, https://doi.org/10.1093/jac/dkag075
23
Prioritization of adverse events related to integrase inhibitors and NNRTIs: a disproportionality analysis using data from the FAERS database
整合酶抑制剂和非核苷类逆转录酶抑制剂相关不良事件的优先级排序：基于FAERS数据库数据的比例失衡分析
Gao-yang Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag074, https://doi.org/10.1093/jac/dkag074
24
Clinical and immunovirological status in children, adolescents and young adults with early-life-acquired HIV: a Spanish multi-cohort analysis since 2020
自2020年以来西班牙多队列分析中，儿童、青少年及青年时期感染HIV者的临床及免疫病毒学状态
Laura Tarancon-Diez and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag079, https://doi.org/10.1093/jac/dkag079
25
Population pharmacokinetics of meropenem in critically ill adult patients receiving extracorporeal membrane oxygenation—an ASAP ECMO study
接受体外膜肺氧合治疗的危重成年患者美罗培南的群体药代动力学——一项ASAP ECMO研究
Mohd H Abdul–Aziz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag090, https://doi.org/10.1093/jac/dkag090
26
Evaluation of HIV-1 transmitted drug-resistance among subtypes circulating from 2022 to 2024 in Italy: a refined analysis through next-generation sequencing
2022年至2024年意大利流行HIV-1亚型间传播耐药性的评估：通过下一代测序技术进行的精细分析
Daniele Armenia and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag084, https://doi.org/10.1093/jac/dkag084
27
Characterization of efflux pump channel of florfenicol for resistance-enhancing variant RE-CmeABC in Campylobacter
耐药增强型变异体RE-CmeABC中氟苯尼考外排泵通道在弯曲菌中的特性研究
Hong Yao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag047, https://doi.org/10.1093/jac/dkag047
28
Genomic characterization of colistin heteroresistance in Acinetobacter baumannii: Evidence for lpxD deletion and collateral sensitivity
鲍曼不动杆菌中黏菌素异质性耐药的基因组特征：lpxD缺失及附带敏感性的证据
Banu Sancak and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag076, https://doi.org/10.1093/jac/dkag076
29
Sustaining stewardship: longitudinal evaluation of an integrated antimicrobial programme in the ICU
持续管理：重症监护室（ICU）综合抗菌药物管理项目的纵向评估
Ashmitha Thomas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag086, https://doi.org/10.1093/jac/dkag086
30
Global dissemination of optrA-mediated linezolid resistance in enterococci
利奈唑胺耐药性基因optrA介导的肠球菌在全球的传播
Jia Qi Beh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag089, https://doi.org/10.1093/jac/dkag089
31
Predicting oral cephalosporin susceptibility in Escherichia coli blood isolates using parenteral cephalosporin susceptibility testing
利用肠外头孢菌素敏感性试验预测大肠杆菌血培养分离株对口服头孢菌素的敏感性
Tho H Pham and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag093, https://doi.org/10.1093/jac/dkag093
32
The pharmacodynamics of polymyxin B in Acinetobacter baumannii in murine thigh and lung infection models
在小鼠大腿和肺部感染模型中多粘菌素B对鲍曼不动杆菌的药效动力学研究
Sanne van den Berg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag097, https://doi.org/10.1093/jac/dkag097
33
Genomic insights into the tmexCD-toprJ: plasmid-mediated evolution, dissemination and diversity in bacterial populations
关于tmexCD-toprJ的基因组见解：质粒介导的细菌群体进化、传播与多样性
Lilan Wan and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag107, https://doi.org/10.1093/jac/dkag107
34
Baseline resistance mutations and virological response to dolutegravir in treatment-naïve patients: a multicentre NGS study
初治患者基线耐药突变与多替拉韦病毒学应答：一项多中心下一代测序（NGS）研究
Alexy Inciarte and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag080, https://doi.org/10.1093/jac/dkag080
35
Novel integrase mutations linked to genotypic DTG resistance in African non-B HIV-1 strains: the DTG RESIST study
非洲非B型HIV-1毒株中与多替拉韦（DTG）基因型耐药相关的新型整合酶突变：DTG耐药研究
Nuri Han and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag088, https://doi.org/10.1093/jac/dkag088
36
Pharmacological evaluation of an ex vivo cervicovaginal HIV prevention model
体外宫颈阴道HIV预防模型的药理学评估
Lindsey B Collins and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag103, https://doi.org/10.1093/jac/dkag103
37
The magnitude of the pharmacodynamic index for NOSO-502: pathogen clearance, emergence of resistance and human dose predictions
NOSO-502药效学指数的幅度：病原体清除、耐药性出现和人体剂量预测
Sanne van den Berg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag106, https://doi.org/10.1093/jac/dkag106
38
Temocillin: a therapeutic alternative in bone and joint infections due to third generation cephalosporin-resistant Enterobacterales?
替莫西林：治疗第三代头孢菌素耐药肠杆菌目引起的骨关节感染的一种替代疗法？
Louise Piquart and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag105, https://doi.org/10.1093/jac/dkag105
39
Metallo-β-lactamase–producing Enterobacterales: cyanide-containing efflux pump inhibitors as potential dual-activity inhibitors
产金属β-内酰胺酶的肠杆菌科细菌：含氰化物的外排泵抑制剂作为潜在的双活性抑制剂
Otávio Hallal Ferreira Raro and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag122, https://doi.org/10.1093/jac/dkag122
40
Outer membrane vesicles transmit blaNDM-5 and package metallo-β-lactamases to promote antibiotic resistance in Escherichia coli
外膜囊泡传递blaNDM-5并包装金属β-内酰胺酶以促进大肠杆菌的抗生素耐药性
Ting-Yin Lu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag123, https://doi.org/10.1093/jac/dkag123
41
Characterization of a ST412-K57 colistin-resistant hypervirulent Klebsiella pneumoniae strain of chicken origin
一株鸡源ST412-K57多粘菌素耐药高毒力肺炎克雷伯菌的特征分析
Qiu Xu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag114, https://doi.org/10.1093/jac/dkag114
42
Olorofim in combination with azole antifungals: results from the Phase 2 salvage therapy study
奥罗芬明与唑类抗真菌药联合使用：2期挽救治疗研究结果
Johan Maertens and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag118, https://doi.org/10.1093/jac/dkag118
RESEARCH LETTER（研究快讯）
43
Infant HIV transmission despite maternal viral suppression: a case of post-weaning seroconversion
母体病毒得到抑制，婴儿仍发生HIV传播：一例断奶后血清转阳病例
Shadia Nakalema and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag072, https://doi.org/10.1093/jac/dkag072
44
Urinary antigen–negative Legionella pneumonia in critically ill patients: value of systematic molecular testing for optimal antimicrobial therapy
危重患者中尿抗原阴性军团菌肺炎：系统分子检测在优化抗菌治疗中的价值
Livia Foglia Manzillo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag101, https://doi.org/10.1093/jac/dkag101
45
Contribution of SHV-1 overexpression to carbapenem resistance in a Klebsiella pneumoniae clinical isolate
SHV-1过表达对某株肺炎克雷伯菌临床分离株碳青霉烯类抗生素耐药性的影响
Céline Plainvert and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag108, https://doi.org/10.1093/jac/dkag108
LETTER TO THE EDITOR（致编辑的信）
46
Comment on: Possible increased risk of Epstein–Barr virus (EBV) infection and posttransplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients
评论：接受莱特莫韦治疗的造血细胞移植受者中，EB病毒（EBV）感染和移植后淋巴增殖性疾病（PTLD）的风险可能增加
Jan Styczynski
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag042, https://doi.org/10.1093/jac/dkag042
47
Comment on: Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis users in Milan, Italy
评论：意大利米兰地区使用多西环素暴露后预防措施人群中针对细菌性性传播感染的抗菌药物使用情况
Luca Bortolani and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag023, https://doi.org/10.1093/jac/dkag023
48
Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes—right to reply
使用聚丙烯腈膜进行连续肾脏替代治疗的患者中卡泊芬净药物治疗监测的回顾性分析——答复权
Antoine Hérault and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag095, https://doi.org/10.1093/jac/dkag095
49
Comment on: Temocillin versus other intravenous beta-lactams for urinary tract infections caused by third-generation cephalosporin-resistant Enterobacterales: a multicentre retrospective matched-cohort study
评论：替莫西林与其他静脉注射β-内酰胺类抗生素治疗第三代头孢菌素耐药肠杆菌目引起的尿路感染：一项多中心回顾性匹配队列研究
Shanshan Ru and Yingzhe Zhang
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag096, https://doi.org/10.1093/jac/dkag096
50
Comment on: Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?
评论：长效糖肽类抗生素：对于最需要它们的患者，获取的障碍是什么，如何克服？
Marco Bongiovanni
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag102, https://doi.org/10.1093/jac/dkag102
51
Comment on ‘Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes’
评论：“对使用聚丙烯腈膜进行连续肾脏替代治疗的患者中卡泊芬净的药理学治疗监测的回顾性分析”
Julien Massol and Frédéric Baud
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag094, https://doi.org/10.1093/jac/dkag094
52
Comment on: ‘Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp’
对“除塞拉蒂亚属（Serratia spp）外肠杆菌目所致心内膜炎的流行病学和治疗”的评论
Gianpiero Tebano and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag098, https://doi.org/10.1093/jac/dkag098
53
‘Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018–2021-right-to-reply’
“比较肺炎球菌疫苗的血清型覆盖率——PCV21（V116，一种新型21价结合肺炎球菌疫苗）与加拿大成人患者中导致侵袭性肺炎球菌疾病的其8种独特肺炎链球菌血清型（15A、15C、16F、23A、23B、24F、31和35B）的流行病学：SAVE研究，2018 - 2021年——回应”
John J Schellenberg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag126, https://doi.org/10.1093/jac/dkag126
54
Comment on: Antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatus
评论：奥罗芬明与伏立康唑对烟曲霉的体外拮抗作用
Corinne Pinder and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag119, https://doi.org/10.1093/jac/dkag119
55
Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp.: right-to-reply
除塞氏杆菌属外肠杆菌科细菌所致心内膜炎的流行病学和治疗：回应
Sunish Shah and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag121, https://doi.org/10.1093/jac/dkag121
Journal of Antimicrobial Chemotherapy Volume 81, Issue 5抗菌化疗杂志81卷 5期
https://academic.oup.com/jac/issue
50TH ANNIVERSARY COLLECTION（50周年纪念合集）
REVIEW（综述）
1
A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 1: setting the stage
针对动基体病的高质量先导化合物及药物开发候选物的战略发现路线图。第一部分：背景介绍
Sarah Hendrickx and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag109, https://doi.org/10.1093/jac/dkag109
REVIEW（综述）
2
Pathophysiology, risk factors and clinical management for polymyxin-associated acute kidney injury
多粘菌素相关急性肾损伤的病理生理学、危险因素及临床治疗
Simiao Zhao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag132, https://doi.org/10.1093/jac/dkag132
SYSTEMATIC REVIEW（系统综述）
3
Definitions and rates of treatment failure in females with uncomplicated urinary tract infection: a systematic literature review
女性单纯性尿路感染治疗失败的定义及发生率：一项系统文献综述
Meghan E Luck and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag112, https://doi.org/10.1093/jac/dkag112
4
Therapeutic drug monitoring and the role of pharmacokinetics/pharmacodynamics in optimizing beta-lactam antibiotic dosing for deep-seated infections: a systematic review
在针对深部感染的β-内酰胺类抗生素优化给药方案中治疗药物监测以及药代动力学/药效学的作用：一项系统综述
Cassandra Vale and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag142, https://doi.org/10.1093/jac/dkag142
ORIGINAL RESEARCH（论著）
5
Optimizing cloxacillin prophylaxis in hip and knee arthroplasty based on population pharmacokinetics of unbound plasma concentrations
基于游离血浆浓度群体药代动力学优化髋关节和膝关节置换术中的氯唑西林预防用药方案
Gustaf Beijer and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag116, https://doi.org/10.1093/jac/dkag116
6
The tissue distribution and pharmacokinetics of [14C]-olorofim following intravenous dosing in the rat
大鼠静脉注射[14C]奥洛罗芬后的组织分布及药代动力学研究
Derek Law and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag120, https://doi.org/10.1093/jac/dkag120
7
Insights from the WHO Tricycle-aligned Fleming Fund EQASIA External Quality Assessment (EQA) programme detecting ESBL-, AmpC- and carbapenemase-producing Escherichia coli in South and South-East Asia
世界卫生组织三轮车项目（Tricycle）协同的弗莱明基金南亚和东南亚地区外部质量评估（EQASIA EQA）计划在检测南亚和东南亚地区产超广谱β-内酰胺酶（ESBL）、AmpC酶和碳青霉烯酶的大肠埃希菌方面的见解
Hiba Al-Mir and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag129, https://doi.org/10.1093/jac/dkag129
8
The plasma and intracellular exposure of intramuscularly administered long-acting cabotegravir and rilpivirine in people with HIV
HIV感染者肌内注射长效卡博特韦和利匹韦林后的血浆及细胞内暴露情况
Micol Ferrara and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag113, https://doi.org/10.1093/jac/dkag113
9
In vitro synergistic activity of minocycline and biapenem against cefiderocol-resistant New Delhi metallo-β-lactamase-producing Enterobacterales
米诺环素与比阿培南在体外对产新德里金属β-内酰胺酶且对头孢地尔耐药的肠杆菌科细菌的协同作用
Takashi Okanda and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag128, https://doi.org/10.1093/jac/dkag128
10
Mortality risk of ESBL producers in Escherichia coli bacteraemia: a comprehensive analysis using the PROBAC cohort
产超广谱β-内酰胺酶大肠埃希菌菌血症的死亡风险：基于PROBAC队列的综合分析
Paula Olivares-Navarro and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag130, https://doi.org/10.1093/jac/dkag130
11
Molecular mechanism of envZ regulating β-lactam antibiotic resistance and virulence in Escherichia coli
EnvZ调控大肠埃希菌β-内酰胺类抗生素耐药性及毒力的分子机制
Kun Yang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag104, https://doi.org/10.1093/jac/dkag104
12
In vitro activity of amoxicillin combined with oral cephalosporins against endocarditis-associated E. faecalis clinical isolates
阿莫西林联合口服头孢菌素针对心内膜炎相关粪肠球菌临床分离株的体外活性
David Luque Paz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag127, https://doi.org/10.1093/jac/dkag127
13
Genome-wide association studies builds a predictive model and reveals novel resistance features for macrolide-resistant Bordetella pertussis
全基因组关联研究构建预测模型并揭示大环内酯类耐药百日咳鲍特菌的新耐药特征
Jialiang Chen and Guowei Liang
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag131, https://doi.org/10.1093/jac/dkag131
14
Real-world validation of a reduced-dose continuous infusion cefepime regimen: pharmacodynamic target attainment, efficacy and neurotoxicity
减量持续静脉输注头孢吡肟方案的实际应用验证：药效学目标达成情况、疗效及神经毒性
Kieffer Korvin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag138, https://doi.org/10.1093/jac/dkag138
15
Cross-species and cross-border spread of aph(3′)-ia-mediated neomycin resistance in Escherichia coli from animals: a genomic perspective
从基因组角度研究动物源大肠杆菌中aph(3′)-ia介导的新霉素耐药性的跨物种和跨国传播
Mattia Pirolo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag143, https://doi.org/10.1093/jac/dkag143
16
Prevalence of cyp51A variants in a US collection of Aspergillus fumigatus clinical isolates and comparative analysis of their contribution to triazole antifungal resistance
美国烟曲霉临床分离株集合中cyp51A变异体的流行情况及其对三唑类抗真菌药物耐药性作用的比较分析
Luisa Fernanda Gómez Londoño and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag124, https://doi.org/10.1093/jac/dkag124
17
In vitro and in vivo activity of daptomycin plus ceftaroline for the treatment of experimental endocarditis due to Enterococcus faecalis with and without high-level aminoglycoside resistance
达托霉素联合头孢洛林对高水平氨基糖苷类耐药及非耐药粪肠球菌所致实验性心内膜炎的体内外疗效研究
María-Alexandra Cañas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag136, https://doi.org/10.1093/jac/dkag136
18
Pharmacokinetics of a three-dose regimen of intramuscular benzathine penicillin G in pregnant women with syphilis
三剂苄星青霉素G肌内注射方案在妊娠期梅毒患者中的药代动力学研究
Eshetie Melese Birru and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag145, https://doi.org/10.1093/jac/dkag145
19
Cefiderocol resistance mediated by mutation of the miniconductance mechanosensitive channel MscM in Klebsiella oxytoca
由产气克雷伯菌中微小电导机械敏感通道MscM发生突变所介导的头孢地尔耐药性
Pia Turowski and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag147, https://doi.org/10.1093/jac/dkag147
20
The veterinary clinic backyard lawn used for relief walks of hospitalized dogs is a hotspot for OXA-type carbapenemases in multiple Enterobacterales
兽医诊所后院供住院犬只散步的草坪是多种肠杆菌科细菌中OXA型碳青霉烯酶的传播热点区域
Yvonne Spahr and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag144, https://doi.org/10.1093/jac/dkag144
21
Pharmacokinetics of cefazolin in bariatric surgery patients: a preoperative perspective
头孢唑林在减肥手术患者中的药代动力学：术前视角
Alexandra Porlier and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag150, https://doi.org/10.1093/jac/dkag150
RESEARCH LETTERS（研究快讯）
22
Plasmid-encoded FRI-10 carbapenemase harboured by non-Enterobacter species isolated from a wastewater sample in Tokyo, Japan
从日本东京废水样本中分离出的非肠杆菌科物种携带质粒编码的FRI-10碳青霉烯酶
Kou Murakami and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag133, https://doi.org/10.1093/jac/dkag133
23
Synergistic activity of cefepime/enmetazobactam with meropenem, piperacillin, piperacillin/tazobactam, cefiderocol and fosfomycin against Klebsiella pneumoniae carrying blaKPC allelic variants
头孢吡肟/恩美唑巴坦与美罗培南、哌拉西林、哌拉西林/他唑巴坦、西他沙星和磷霉素针对携带blaKPC等位基因变体的肺炎克雷伯菌的协同作用
Alice Crema and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag141, https://doi.org/10.1093/jac/dkag141
24
MRSA and carbapenem-resistant Acinetobacter baumannii on the fall: successful infection prevention and control in Chilean ICUs
耐甲氧西林金黄色葡萄球菌和耐碳青霉烯类鲍曼不动杆菌数量下降：智利重症监护病房感染预防与控制的成功案例
Patricio Ross and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag146, https://doi.org/10.1093/jac/dkag146
LETTER TO THE EDITOR（致编辑的信）
25
Comment on: Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic–pharmacodynamic modelling in adults and infants
评论：基于模型的评估VRC07-523LS在婴儿中的给药剂量——基于成人和婴儿群体药代动力学-药效学模型
Wanhua Qiu
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag139, https://doi.org/10.1093/jac/dkag139
26
Comment on: Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018–21
评论：比较含21种血清型的肺炎球菌疫苗PCV21（V116）（一种新型21价结合肺炎球菌疫苗）的血清型覆盖范围，以及2018 - 2021年SAVE研究中导致加拿大成年患者侵袭性肺炎球菌疾病的8种独特肺炎链球菌血清型（15A、15C、16F、23A、23B、24F、31和35B）的流行病学情况
Gokul Raj Pullagura and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag125, https://doi.org/10.1093/jac/dkag125
27
Comment on: Distinct population structure and genomic context of NarAB between broiler and human clinical Enterococcus isolates
评论：肉鸡源和人临床来源肠球菌分离株中NarAB的不同种群结构和基因组背景
Alex Wong
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag134, https://doi.org/10.1093/jac/dkag134
28
Distinct population structure and genomic context of narAB between broiler and human clinical Enterococcus isolates—authors’ response
肉鸡源和人临床来源肠球菌分离株中narAB的不同种群结构和基因组背景——作者回复
Jayanth Balakuntla and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag135, https://doi.org/10.1093/jac/dkag135
Journal of Antimicrobial Chemotherapy Volume 81, Issue 6抗菌化疗杂志81卷 6期
https://academic.oup.com/jac/issue
50TH ANNIVERSARY COLLECTION（50周年纪念合集）
REVIEW（综述）
1
A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 3: from lead towards a drug development candidate
针对动基体疾病高质量先导化合物和药物开发候选物的战略发现路线图。第三部分：从先导化合物到药物开发候选物
Sarah Hendrickx and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag111, https://doi.org/10.1093/jac/dkag111
ORIGINAL RESEARCH（原创研究）
2
Population pharmacokinetics and probability of target attainment of tigecycline in critically ill children
危重患儿中替加环素（Tigecycline）的群体药代动力学及目标达成概率研究
Wenjuan Hu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag156, https://doi.org/10.1093/jac/dkag156
3
Phenotypic and genotypic characterization of HMB-3, a metallo-beta-lactamase from Pseudomonas asiatica
假单胞菌属亚洲种（Pseudomonas asiatica）中金属β-内酰胺酶HMB-3的表型和基因型特征
Jacqueline Findlay and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag148, https://doi.org/10.1093/jac/dkag148
4
Early adequate linezolid concentrations and clinical outcomes in confirmed Gram-positive infections: the role of therapeutic drug monitoring
确诊的革兰氏阳性菌感染中早期达到适宜利奈唑胺浓度与临床预后的关系：治疗药物监测的作用
Daniel Fresán and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag137, https://doi.org/10.1093/jac/dkag137
5
Monte Carlo simulations identify suboptimal PK/PD target attainment with standard maribavir dosing
蒙特卡洛模拟表明标准剂量马立巴韦的药动学/药效学靶标达成情况欠佳
Yeleen Fromage and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag153, https://doi.org/10.1093/jac/dkag153
6
Exploring the pharmacokinetic mechanisms that affect bictegravir exposure during pregnancy
探究妊娠期间影响比克替拉韦暴露的药代动力学机制
L van der Wekken-Pas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag159, https://doi.org/10.1093/jac/dkag159
7
Artificial intelligence for analysing antibiotic use: an exploratory study in a tertiary care paediatric hospital in Italy
人工智能用于分析抗生素使用情况：意大利一家三级儿科医院的探索性研究
Elio Castagnola and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag162, https://doi.org/10.1093/jac/dkag162
8
Antimicrobial activity of aztreonam–avibactam against KPC variant-producing Klebsiella pneumoniae with ceftazidime–avibactam resistance
氨曲南-阿维巴坦对产KPC变异体且对头孢他啶-阿维巴坦耐药的肺炎克雷伯菌的抗菌活性
Jingchun Kong and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag152, https://doi.org/10.1093/jac/dkag152
9
Highly transformable Haemophilus influenzae as a potential amplifier of quinolone resistance dissemination
高转化型流感嗜血杆菌作为喹诺酮耐药性传播的潜在放大器
Takeaki Wajima and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag160, https://doi.org/10.1093/jac/dkag160
10
Comparative nephrotoxicity of polymyxin B versus colistin: evidence from ensemble learning and propensity score matching
多黏菌素B与黏菌素的肾毒性比较：来自集成学习和倾向评分匹配的证据
Murat Özdede and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag044, https://doi.org/10.1093/jac/dkag044
11
Emulating a target trial of early compared with late initiation of appropriate antibiotic therapy for hospital-acquired monobacterial Gram-negative bloodstream infections
模拟医院获得性单菌革兰氏阴性菌血流感染早期与晚期开始恰当抗生素治疗的对照试验
Abdullah T Aslan and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag161, https://doi.org/10.1093/jac/dkag161
12
Flufenamic acid resensitizes MRSA to gentamicin through synergistic ion modulation
氟苯尼考通过协同离子调节使MRSA对庆大霉素重新敏感
Xiaomin Ren and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag154, https://doi.org/10.1093/jac/dkag154
13
Description of OXA-244 carbapenemase-producing Escherichia coli in farm animals in The Netherlands, 2024
2024年荷兰农场动物中OXA-244碳青霉烯酶产大肠杆菌的描述
K T Veldman and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag155, https://doi.org/10.1093/jac/dkag155
14
Clinical outcomes of beta-bactam monotherapy versus beta-lactam plus azithromycin in hospitalized patients with community-acquired pneumoniae
β-内酰胺类单药治疗与β-内酰胺类联合阿奇霉素治疗社区获得性肺炎住院患者的临床预后比较
Ilona Zhygalova Zhygalova and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag158, https://doi.org/10.1093/jac/dkag158
15
‘Leaving no stones unturned’: up to 10 years results on the effectiveness, tolerability and metabolic safety of dolutegravir+lamivudine (DTG+3TC) as a switch regimen in the ODOACRE cohort
"不遗余力"：ODOACRE队列中多替拉韦+拉米夫定（DTG+3TC）作为转换方案长达10年的有效性、耐受性及代谢安全性结果
Arturo Ciccullo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag172, https://doi.org/10.1093/jac/dkag172
16
Evaluation of a novel lateral flow immunochromatographic assay, Certest ResisCheck® Carbapenemases, for the rapid detection and differentiation of carbapenemase in Gram-negative bacteria from bacterial culture
新型侧向流免疫层析检测试剂Certest ResisCheck® Carbapenemases用于革兰氏阴性菌培养物中碳青霉烯酶快速检测与鉴别的评估
Laura Monge-Olivares and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag149, https://doi.org/10.1093/jac/dkag149
17
Temocillin efficacy and emergence of resistance in Enterobacter cloacae Complex in a murine peritonitis model
替莫西林对产气肠杆菌复合群的疗效及耐药性演变：小鼠腹膜炎模型研究
N Alanbari and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag151, https://doi.org/10.1093/jac/dkag151
18
Temporal association between aerosolized colistin use and colistin resistance in the ICU: a time-series analysis
ICU中雾化粘菌素使用与粘菌素耐药之间的时间关联：一项时间序列分析
Weechang Kang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag169, https://doi.org/10.1093/jac/dkag169
19
Can antimicrobial stewardship programmes be implemented during an armed conflict? A retrospective interventional cohort study
武装冲突期间能否实施抗菌药物管理计划？一项回顾性干预性队列研究
Hailie D Uren and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag115, https://doi.org/10.1093/jac/dkag115
20
Voriconazole therapy and CYP2C19 phenotype: identifying patients who may need alternative antifungal therapy
伏立康唑治疗与CYP2C19表型：识别可能需要替代抗真菌治疗的患者
Eman Wehbe and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag168, https://doi.org/10.1093/jac/dkag168
21
Impact of cardiopulmonary bypass on cefuroxime plasma and interstitial tissue concentrations in patients undergoing cardiac bypass surgery—a prospective controlled clinical trial
体外循环对心脏旁路手术患者头孢呋辛血浆及组织间质浓度的影响——一项前瞻性对照临床试验
Stefanie Nothofer and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag171, https://doi.org/10.1093/jac/dkag171
22
Population pharmacokinetic analysis and dosing regimen optimization of eravacycline in critically ill patients with carbapenem-resistant Acinetobacter baumannii pneumonia
对碳青霉烯耐药鲍曼不动杆菌肺炎危重患者中埃拉环素的药代动力学分析及给药方案优化
Luqi Lou and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag178, https://doi.org/10.1093/jac/dkag178
23
Durability and mechanistic performance of aztreonam/avibactam versus aztreonam plus ceftazidime/avibactam against Stenotrophomonas maltophilia complex
氨曲南/阿维巴坦与氨曲南联合头孢他啶/阿维巴坦对抗嗜麦芽窄食单胞菌复合群的耐久性和机制性能比较
Ashlan J Kunz Coyne and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag177, https://doi.org/10.1093/jac/dkag177
24
High-dose daptomycin for the treatment of invasive infections due to Enterococcus faecalis isolates with intermediate susceptibility
高剂量达托霉素治疗粪肠球菌中介敏感株所致侵袭性感染的疗效
Sidney Drake and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag179, https://doi.org/10.1093/jac/dkag179
25
Updated mapping of Plasmodium falciparum kelch13 gene polymorphisms in Madagascar, 2024
2024年马达加斯加恶性疟原虫kelch13基因多态性的最新图谱更新
Camille Roesch and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag181, https://doi.org/10.1093/jac/dkag181
26
Efficacy of ceftazidime/avibactam against 10 clinical isolates of Pseudomonas aeruginosa in icodextrin-based peritoneal dialysis solution and patient-derived dialysate
头孢他啶/阿维巴坦针对icodextrin基腹膜透析液及患者来源透析液中10株铜绿假单胞菌临床分离株的抗菌活性
Stephanie Supparitsch and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag185, https://doi.org/10.1093/jac/dkag185
27
Cefiderocol activity against multidrug-resistant isolates from the PERSEUS study: relationship between cefiderocol minimum inhibitory concentration and clinical outcomes
头孢德罗对PERSEUS研究中多重耐药分离株的抗菌活性：头孢德罗最低抑菌浓度与临床预后之间的关系
Rafael Cantón and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag164, https://doi.org/10.1093/jac/dkag164
28
Class 1 DISARM system in restriction of conjugative carbapenemase-encoding plasmids in Klebsiella pneumoniae sequence type 23
1类DISARM系统对肺炎克雷伯菌ST23中接合型碳青霉烯酶编码质粒的限制作用
Qingqing Du and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag167, https://doi.org/10.1093/jac/dkag167
29
Acute kidney injury following amikacin therapy: a retrospective cohort study
阿米卡星治疗后急性肾损伤：一项回顾性队列研究
Iris Zohar and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag188, https://doi.org/10.1093/jac/dkag188
30
Performance of EUCAST disc diffusion and supplementary methods to detect reduced susceptibility to linezolid in enterococci— the NordicAST LRE-study
EUCAST纸片扩散法及补充方法检测肠球菌利奈唑胺低敏感性的表现——NordicAST LRE研究
Bjørg Christina Haldorsen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag174, https://doi.org/10.1093/jac/dkag174
31
In vitro exposure to non-antipseudomonal antibiotics (NAPA) induces Pseudomonas aeruginosa resistance to antipseudomonal antibiotics (APA)
体外暴露于非抗假单胞菌抗生素（NAPA）可诱导铜绿假单胞菌对抗假单胞菌抗生素（APA）产生耐药性
David Lasry and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag182, https://doi.org/10.1093/jac/dkag182
32
Sub-inhibitory polyether ionophores enhance resistance plasmid transfer and transiently perturb the broiler gut resistome
亚抑制浓度的聚醚离子载体可促进耐药质粒转移并暂时扰乱肉鸡肠道耐药组
Jingyue Yang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag190, https://doi.org/10.1093/jac/dkag190
33
Influence of a putative TonB-dependent receptor on cefiderocol susceptibility in clinical Enterobacter hormaechei isolates
推测的TonB依赖性受体对临床肠杆菌hormaechei分离株中头孢地尔敏感性的影响
Pia Turowski and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag193, https://doi.org/10.1093/jac/dkag193
RESEARCH LETTERS（研究快报）
34
Early bictegravir failure and emergence of R263K-mediated class-wide HIV integrase inhibitors resistance linked to over-the-counter supplement use
比克替拉韦早期治疗失败与R263K介导的与非处方补充剂使用相关的全类HIV整合酶抑制剂耐药的出现
Elisa Minacori and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag157, https://doi.org/10.1093/jac/dkag157
35
Environmental benefits of switching from intravenous to oral administration of ciprofloxacin
环丙沙星从静脉给药转换为口服给药的环境效益
Nicolas De Jaegher and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag163, https://doi.org/10.1093/jac/dkag163
36
Macrolide resistance via 23S rRNA gene mutation in Corynebacterium ulcerans
白喉棒状杆菌通过23S rRNA基因突变介导的大环内酯类耐药
Chiara Crestani and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag166, https://doi.org/10.1093/jac/dkag166
37
Prosthesis-associated Burkholderia cepacia complex infection managed with sequential directed therapy including ceftolozane/tazobactam
采用包括头孢妥仑/他唑巴坦在内的序贯导向疗法治疗假体相关洋葱伯克霍尔德菌复合感染
Elia Asensi-Díaz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag165, https://doi.org/10.1093/jac/dkag165
38
Drug interactions and kidney safety of bictegravir/emtricitabine/tenofovir alafenamide in kidney transplant recipients with HIV: an interventional pilot study
比克替拉韦/恩曲他滨/丙酚替诺福韦在合并HIV的肾移植受者中的药物相互作用及肾脏安全性：一项干预性 pilot 研究
Thomas Stehlé and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag176, https://doi.org/10.1093/jac/dkag176
39
Harmonizing antimicrobial susceptibility testing: a comparison of CLSI and EUCAST categorizations
抗菌药物敏感性试验的协调：CLSI与EUCAST分类法的比较
Eric Farfour and Marie Lavollay
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag081, https://doi.org/10.1093/jac/dkag081
LETTER TO THE EDITOR（致编辑的信）
40
Comment on: Impact of loading dose β-lactam therapy on outcomes of KPC-producing Klebsiella pneumoniae bloodstream infections in non-ICU patients: a real world study
对"负荷剂量β-内酰胺类治疗对非ICU患者产KPC肺炎克雷伯菌血流感染结局的影响：一项现实研究"的评论
Xuefeng Yu
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag173, https://doi.org/10.1093/jac/dkag173
41
Comment on: ‘Cooperation between HIV-1 integrase natural polymorphism K156N and 3′PPT mutations in dolutegravir monotherapy failure’
评论："HIV-1整合酶天然多态性K156N与3′PPT突变在多替拉韦单药治疗失败中的协同作用"
Muhammad Ifham Hanif and Mentari Maratus Sholihah
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 6, June 2026, dkag175, https://doi.org/10.1093/jac/dkag175
100 项与 呼吸道合胞病毒疫苗（辉瑞大药厂） 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 呼吸道合胞病毒肺炎 | 欧盟 | 2023-08-23 | |
| 呼吸道合胞病毒肺炎 | 冰岛 | 2023-08-23 | |
| 呼吸道合胞病毒肺炎 | 列支敦士登 | 2023-08-23 | |
| 呼吸道合胞病毒肺炎 | 挪威 | 2023-08-23 | |
| 呼吸道合胞体病毒感染 | 美国 | 2023-05-31 | |
| 下呼吸道感染 | 加拿大 | 2023-01-04 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 呼吸道感染 | 临床3期 | 美国 | 2020-06-17 | |
| 呼吸道感染 | 临床3期 | 日本 | 2020-06-17 | |
| 呼吸道感染 | 临床3期 | 阿根廷 | 2020-06-17 | |
| 呼吸道感染 | 临床3期 | 澳大利亚 | 2020-06-17 | |
| 呼吸道感染 | 临床3期 | 巴西 | 2020-06-17 | |
| 呼吸道感染 | 临床3期 | 加拿大 | 2020-06-17 | |
| 呼吸道感染 | 临床3期 | 智利 | 2020-06-17 | |
| 呼吸道感染 | 临床3期 | 丹麦 | 2020-06-17 | |
| 呼吸道感染 | 临床3期 | 芬兰 | 2020-06-17 | |
| 呼吸道感染 | 临床3期 | 冈比亚 | 2020-06-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床3期 | 378 | Placebo | 範蓋鹹醖顧鹹製鹽鹽艱 = 積夢窪築齋願構築餘糧 鑰糧艱襯遞夢廠製蓋繭 (衊醖醖獵築廠選憲壓範, 壓鑰衊鏇繭衊醖簾糧鬱 ~ 選鑰鑰蓋鑰齋餘夢糧糧) 更多 | - | 2026-02-09 | ||
临床3期 | 453 | (RSVpreF (With Preservative, MDV)) | 齋簾觸觸鹽築壓觸鹹鹹(構獵願窪衊願觸衊鹽製) = 襯糧鏇膚壓鑰廠獵廠廠 簾選網選鏇壓淵構夢襯 (網製構齋鹽顧蓋鹽艱遞, 願範艱憲網糧築網願鑰 ~ 積鑰鹽蓋窪憲積醖襯夢) 更多 | - | 2025-09-25 | ||
(RSVpreF (Without Preservative, SDV)) | 齋簾觸觸鹽築壓觸鹹鹹(構獵願窪衊願觸衊鹽製) = 餘製鏇壓夢鬱鬱夢醖壓 簾選網選鏇壓淵構夢襯 (網製構齋鹽顧蓋鹽艱遞, 網醖觸顧淵夢製鑰鹽積 ~ 糧願艱窪築鑰醖窪鏇鹹) 更多 | ||||||
临床3期 | 885 | SSA+RSVpreF (SSA: RSVpreF) | 鹹鏇憲鏇願艱積構鹹築 = 簾鹽製鹹餘簾膚醖鹹鹹 鬱鹹製選鬱淵壓構憲夢 (顧遞鬱鏇鹽齋積淵醖糧, 鬱蓋遞窪構膚鏇製積遞 ~ 壓顧蓋艱鬱鹹遞壓艱獵) 更多 | - | 2025-08-08 | ||
SSA (SSA: Placebo) | 鹹鏇憲鏇願艱積構鹹築 = 願製鑰獵選構淵構齋艱 鬱鹹製選鬱淵壓構憲夢 (顧遞鬱鏇鹽齋積淵醖糧, 糧鹽窪鹹廠鑰選憲糧顧 ~ 築壓餘觸淵網鹹構網淵) 更多 | ||||||
临床3期 | 14,727 | (Infant Participants: RSVpreF) | 鏇簾糧壓鏇鹹餘獵網糧 = 夢廠餘願製夢夢遞壓鹽 鏇糧顧窪壓鏇淵製襯簾 (廠鏇網範觸廠餘觸積醖, 範鑰鏇網願鹹鬱窪窪鏇 ~ 製顧簾憲鹹淵範選壓醖) 更多 | - | 2025-02-11 | ||
placebo+RSVpreF (Infant Participants: Placebo) | 鏇簾糧壓鏇鹹餘獵網糧 = 遞製衊膚選淵糧繭製選 鏇糧顧窪壓鏇淵製襯簾 (廠鏇網範觸廠餘觸積醖, 鏇網廠鏇壓窪獵廠簾範 ~ 鹹鑰壓繭襯簾鏇糧網憲) 更多 | ||||||
临床3期 | - | - | Bivalent RSV Prefusion F (RSVpreF) Vaccine (RSVpreF 120-µg) | 鹹鹹膚選餘範糧襯糧遞(餘繭積壓鬱鏇願繭簾鑰) = 襯膚蓋願蓋繭積膚糧廠 遞淵積遞鑰積憲觸構構 (鹹鏇餘觸鏇構壓衊襯鑰 ) | 积极 | 2025-02-10 | |
Bivalent RSV Prefusion F (RSVpreF) Vaccine (Placebo) | 鹹鹹膚選餘範糧襯糧遞(餘繭積壓鬱鏇願繭簾鑰) = 淵鹽鏇夢壓淵選遞築鹹 遞淵積遞鑰積憲觸構構 (鹹鏇餘觸鏇構壓衊襯鑰 ) | ||||||
临床3期 | - | Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine (RSVpreF) | 廠繭衊壓遞鏇積繭蓋壓(壓獵網壓製繭餘選積觸) = no clinically significant increase in adverse events of special interest, including preterm birth, low birth weight, or neonatal hospitalization, was observed among pregnant people in the overall analysis 觸鬱壓艱糧夢繭壓鏇願 (鏇觸遞壓積繭鬱壓窪齋 ) 更多 | 积极 | 2025-02-01 | ||
Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine (Placebo) | |||||||
临床3期 | 203 | 範廠積製醖壓夢築淵糧(醖壓顧顧蓋衊壓鹽襯醖) = ABRYSVO was well-tolerated during the trial, showing a safety profile consistent with findings from other studies of the vaccine. 鹽齋壓窪淵觸觸糧蓋構 (窪鑰範淵鑰願網壓齋膚 ) 更多 | 积极 | 2024-08-12 | |||
临床2期 | 70 | (RSVPreF) | 廠築鑰鹽鏇願獵鹽鹹憲(廠衊衊壓範積鬱遞鹹製) = 觸窪獵遞襯網窪鬱繭觸 衊網網廠鹹壓衊廠鏇憲 (遞積簾鑰餘觸餘餘廠鹹, 糧醖獵範鬱鬱餘鬱憲憲 ~ 齋鬱鬱鹹鏇壓廠繭選積) 更多 | - | 2024-08-07 | ||
Placebo (Placebo) | 廠築鑰鹽鏇願獵鹽鹹憲(廠衊衊壓範積鬱遞鹹製) = 壓積鹹衊觸選夢築衊鬱 衊網網廠鹹壓衊廠鏇憲 (遞積簾鑰餘觸餘餘廠鹹, 夢顧選選醖積構膚襯願 ~ 廠範簾壓廠選鹽範製製) 更多 | ||||||
临床3期 | - | RSVpreF vaccine | 築窪糧鹽鹹壓鏇製憲願(齋襯醖繭築簾築網淵遞) = 膚鑰窪艱鬱淵鹽餘艱艱 網襯鏇構鬱繭膚範鹽鏇 (餘構鹹餘繭壓鹽網網鹹 ) 更多 | 积极 | 2024-06-08 | ||
bivalent RSVpreF maternal vaccination (Placebo) | 築窪糧鹽鹹壓鏇製憲願(齋襯醖繭築簾築網淵遞) = 膚襯願鑰醖鏇淵廠餘鑰 網襯鏇構鬱繭膚範鹽鏇 (餘構鹹餘繭壓鹽網網鹹 ) 更多 | ||||||
临床3期 | - | 餘範製蓋壓糧觸膚顧艱(繭衊積壓憲鹽製憲觸糧) = Participants demonstrated RSV-A and RSV-B subgroup neutralizing responses non-inferior to the response seen in the Phase 3 (NCT05035212) RENOIR study of ABRYSVO in more than 34,000 adults aged 60 or older where vaccine efficacy was previously demonstrated. 餘糧範鬱鑰鏇鬱觸艱淵 (遞膚繭鬱簾夢鑰願鹽範 ) 达到 更多 | 积极 | 2024-04-09 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用